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Abstract

THE EXPRESSION AND FUNCTION OF WILMS' TUMOR 1 IN MALIGNANT
GLIOMA
By Aaron J. Clark, B.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2006
Major Director: William C. Broaddus, M.D., Ph.D
Hord Professor
Department of Neurosurgery, Department of Anatomy and Neurobiology

The Wilms' tumor 1 gene is overexpressed in many types of cancer and is
associated with poor prognosis and resistance to anti-cancer therapies. In vitro studies in
non-glioma cells types have demonstrated that WTl plays a role in increased proliferation,
resistance to apoptosis, and increased cellular invasion. We aimed to thoroughly
characterize the expression pattern of Wilms' tumor 1 in human malignant glioma and
discern its function in this complex disease process. We screened a large sample of
established human malignant glioma cell lines and glioma tissue specimens of all grades
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for WT1 expression. The majority of cell lines and 80% of all glioma tissue expressed
WTI mRNA, all of which expressed WTl(+KTS) isoforms. Further screening of the
glioblastoma specimens for p53 mutation followed by logistic regression analysis
demonstrated a positive correlation between WTl expression and wild-type p53 ( p = 0.04).
To determine if WTl and p53 functionally interacted, we generated LN-229 glioblastoma
cells that stably expressed WTl. As LN-229 cells harbor a p53 mutation, transient
transfection with wild-type p53 induced apoptosis. However, stable WTI expression did
not protect cells from p53-mediated cell death. We then generated U87MG cells (p53
wild-type) that stably expressed WT1 to model an endogenous p53 response. It is well
known that after treatment with ionizing radiation, U87MG cells readily undergo p53mediated apoptosis. Again, WTI expression did not protect against ionizing radiationinduced p53-mediated cell death. We next examined the effect of transient WTI silencing
on ionizing radiation induced cell death in T98G and LN-18 cells which express
endogenous WTl. Combination treatment with ionizing radiation and silencing of WTI
using short interfering RNA caused a decrease in viability and clonogenic survival relative
to radiation alone in both cell lines. Lastly, we studied the effect of stable WTl silencing
using short hairpin RNA on glioblastoma cell tumorigenicity. Stable transduction of
U25 1MG and LN-18 cells with WTI short hairpin RNA resulted in a marked decrease in
proliferation. WTI silencing in U251MG cells also caused a decrease in in vitro invasion.
WTl silencing in U25 1MG cells caused an increase in tumor latency and a decrease in
tumor growth rate when cells were used to subcutaneously inoculate nude mice. Not only
do these studies support an oncogenic role for WTI in glioma biology, they provide

X

encouraging evidence that WTl may be a therapeutic target for molecular treatment of
glioblastoma.

CHAPTER 1.

INTRODUCTION
THE OVERLAP BETWEEN GLIOBLASTOMA AND WILMS'
TUMOR 1 BIOLOGY
Abstract
Glioblastoma is the most aggressive and most common primary brain tumor which,
despite maximal treatment efforts, carries a poor prognosis. Numerous molecular changes
have been characterized which may partially explain the extreme resistance of
glioblastoma cells to surgery, radiotherapy, and chemotherapy. In spite of these advances
in knowledge, a comparable increase in patient survival has not been attained. Further
genetic characterization of these tumors promises to uncover additional targets for directed
therapies which have the potential for use in combination with traditional therapies. One
such gene may be the Wilms tumor I (WT1) gene. WTI has joined the ranks of a growing
number of gene products critical for development and differentiation that become
dysregulated during tumorigenesis. WTI is expressed in the normal developing central
nervous system (CNS) and may play a role in neuronal differentiation. In the adult, WTl
expression in the brain is restricted to the area postrema, but is aberrantly overexpressed in
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the majority of gliomas of all grades. Several physiologic and pathologic functions of
WT1 suggest possible roles in glioblastoma, including trans-activation of growth factor
and growth factor receptor genes, transcriptional regulation of cell cycle regulatory genes,
interaction with the p53 tumor suppressor, and modulation of cell motility and invasion.
Future study of WT1 in glioblastoma may establish its oncogenic role and its potential as
an efficacious therapeutic target. Here we review malignant glioma clinical behavior and
molecular genetics with an emphasis on pathways that may be modulated by WTl, the
molecular biology of which is then extensively described.
Brain tumor classification and grading

Neuroectodermal tumors, whether arising in the central or peripheral nervous
system, are classified according to the cell of origin, as determined by morphology and
immunohistochemistry of the predominant cell type comprising the tumor. This
classification system is largely based on the seminal work of Harvey Cushing and his
colleague Percival Bailey in the early 1900's, who were investigating methods of
correlating outcome with histology[l]. The gliomas are central nervous system
neuroectodermal tumors of glial origin and include astrocytomas, oligodendrogliomas,
mixed gliomas, ependymomas and a variety of other glial tumor types. Gliomas can arise
throughout the brain, brain stem, and spinal cord, but most commonly occur in the deep
white matter of the cerebral hemispheres[l]. Because gliomas rarely metastasize outside
of the central nervous system (CNS), staging of these tumors is not performed[l84].
Rather, gliomas are graded I - IV according to the histological determination of
malignancy described by the World Health Organization (WHO) grading system[l04].

The WHO grading system is based on the presence of nuclear atypia, vascular
proliferation, mitotic figures, and necrosis[l]. Grade I gliomas are benign, wellcircumscribed, and often curable tumors while grades I1 - IV correspond to increasingly
malignant and invasive tumors that prove difficult to eradicate.

Epidemiology of brain tumors
Primary brain tumors of all grades, when considered as a group, are a relatively rare
type of tumor with an incidence rate of 14.8 cases per 100,000 person-years, according to
the Central Brain Tumor Registry of the United States[27]. In 2005, an estimated 43,800
brain tumors were diagnosed in the United States. However, brain tumors are very
prevalent in certain populations and responsible for significant morbidity. They are the
most common solid tumor in children ages 0 - 19 and the second most common cancer
following leukemia in this age group. They were also the leading cause of cancer death
among children and young adult men ages 20 - 34 in 2000. Malignant primary brain
tumors constitute a large proportion of all primary brain tumors and therefore have a high
mortality rate. It is estimated that 21,690 primary brain tumors diagnosed in 2005 will be
malignant causing an estimated 12,760 deaths.
Epidemiolow of glioblastoma

The gliomas account for 40% of all primary brain tumors[27]. The diffuse
astrocytomas comprise more than 80% of the gliomas and include grade I1 astrocytoma,
anaplastic astrocytoma (grade 111), and glioblastoma (grade IV). Anaplastic astrocytoma
and glioblastoma are often collectively referred to as the malignant gliomas. In addition to
being the most deadly brain tumor, glioblastoma is also the most common primary
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malignant brain tumor accounting for 20.3% of all primary brain tumors and 50.7% of
gliomas. The incidence of glioblastoma increases with age with a median age at diagnosis
of 64. Incidence rates of glioblastoma are 1.6 times higher in males than females and 2
times higher in whites than blacks[l71]. Although the cause is unknown, the incidence of
glioblastoma appears to have increased between 1977 and 2000, particularly in the
elderly[82].
In spite of high quality ep@emiologic data, few risk factors and predisposing
conditions have been definitively identified. Whole brain radiation during childhood is the
only known risk factor for sporadic glioma. A large cohort of children treated for acute
lymphoblastic leukemia (ALL) was retrospectively analyzed for development of secondary
neoplasms[l69]. Nearly half of all secondary neoplasms were malignant gliomas and all
occurred in children who had received cranial radiation. These results could be interpreted
to indicate an interaction between DNA damaging therapies and underlying genetic
predispositions to cancer. In fact, several genetic syndromes include predisposition to
glioma development and the tumor suppressor genes involved provide clues to their role in
sporadic gliomagenesis[l49]. The hereditary tumor syndromes neurofibromatosis types 1
and 2, tuberous sclerosis con~plex,Li-Fraumeni syndrome, melanoma-astrocytoma
syndrome, and Turcot syndrome include predisposition to glioma formation.
Neurofibromatosis type 1 and tuberous sclerosis complex predispose to optic glioma and
subependymal giant cell astrocytomas, respectively, both generally benign tumors while
the others confer risk of diffuse astrocytoma development including glioblastoma. The
mutations underlying these syndromes and their propensity for development of glioma
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demonstrates the importance of molecular pathways which will be mentioned here and
discussed in more detail below (please see "Glioblastoma molecular biology").
Neurofibromatosis type 1 is caused by germ line mutation of the tumor suppressor NF1.
Its tumor suppressive function derives from its ability to maintain the proto-oncogene Ras
in an inactive GTP-bound state, as demonstrated by observational studies in tumor cell
lines derived from NFl tumor specimens[41]. In sporadic gliomagenesis, Ras is a critical
downstream transducer of growth factor receptor mediated signaling. Li-Fraumeni
syndrome is caused by mutation of the tumor suppressor p53, which is mutated or
otherwise functionally inactivated in a significant proportion of sporadic gliomas[l39].
P53 exerts its function by inducing cell cycle arrest and/or apoptosis in response to DNA
damage, including oncogenic mutations[l32]. Melanoma-astrocytoma syndrome is
associated with loss of the CDKN2A locus which encodes two tumor suppressors; p16 INK4a
and pl 9ARF,both of which are commonly lost in sporadic glioblastoma[9]. P16INK4a is
responsible for maintaining the retinoblastoma (Rb) tumor suppressor in an active state,
while p l 9ARFfunctions by preventing p53 degradation. Familial glioma syndromes have
also been reported in the absence of other tumor predisposition syndromes but the
causative lesion is unknown.
Clinical features, prognosis, and treatment of glioblastoma
The classically described triad of symptoms for glioblastoma on presentation are;
headache, seizure, and hemiparesis. The preliminary diagnosis of glioblastoma is
generally made by identification of characteristic radiographic features. Biopsy and
subsequent histologic classification are required for definitive diagnosis. Diagnosis of
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glioblastoma confers a poor prognosis with a median survival of approximately 1 year and
a five year survival is less than 4%[27, 1481. Analysis of over 1500 patients enrolled in
Radiation Therapy Oncology Group clinical trials demonstrated that prognosis within this
narrow range is predicted by age, histology, Karnofsky Performance Scale (KPS) score,
mental/neurologic status, extent of surgical resection, and dose of radiation[2 141.
Specifically, younger age, less malignant histology, higher KPS score and neurologic
function, and more aggressive treatment are associated with improved prognosis.
Recently, microarray analysis of a large sample of malignant gliomas followed by
classification based on gene expression profiles was shown to better predict survival than
histopathologic analysis[l70]. A similar study found that gene expression profiling based
on microarray analysis of tumor tissue extracts identified novel genes associated with
prognosis that were superior to the predictive power of established glioma-associated
genetic changes[l99]. These findings suggest that complete molecular characterization of
gliomas may improve prognosis prediction. The genetic analysis of long term survivors
(those surviving greater than 3 years, LTS) is intriguing as survival past three years is
associated with extended disease-free survival[21]. Comparative genomic hybridization
was used to compare genetic changes in LTS tumors compared with those patients
surviving less than 1.5 years. Loss of chromosome 19q was associated with LTS in this
study[21]. Studies such as these highlight the importance of such analyses not only in
distinguishing different prognostic groups but also by identifying changes that determine
disease progression. Future treatments may feature standard therapy supplemented with
targeted molecular therapies based on the results of such studies. Current standard of care

7
for patients with glioblastoma is surgical resection followed by radiotherapy and adjuvant
chemotherapy.

Surgery for glioblastoma
The goals of surgery for glioblastoma are relief of neurologic symptoms caused by
the expanding mass, obtaining a definitive diagnosis, and cytoreduction[235]. Aggressive
surgery for glioblastoma is controversial as wider margins of resection carry the risk of
inducing iatrogenic neurologic deficits. However, studies have shown that open
craniotomy for tumor resection yields superior survival relative to biopsy alone[ll3]. In
addition, extent of resection improves survival suggesting that cytoreduction of malignant
cells is crucial for disease contro1[224, 1181. Glioblastoma cell invasiveness remains the
major obstacle to eliciting a surgical cure. In 1961, Matsukado et a1 reviewed 100
necropsy specimens and showed that 4711 00 had invaded the corpus collosum to involve
both cerebral hemispheres, demonstrating the classic "butterfly glioma" pattern[l42].
Most agree that these tumors cannot be completely resected. Furthermore, with the
exception of tumors located in the tip of the frontal lobe, all tumors that involved a single
hemisphere had spread into adjacent lobes. Microscopically, tumor cells were present
beyond the gross demarcation between tumor and normal tissue. A more recent study
demonstrated that, in a significant number of glioblastoma specimens (311 5), tumor cells
were detected at autopsy more than 2 cm outside the enhancing margin shown on
computerized tomography (CT) scans[20]. Taken together, this study indicates that
invading cells make gross total resection, even when utilizing intraoperative CT image
guidance systems, difficult and, in nearly half of cases, impossible. In the fbture,
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cytoreductive surgery combined with molecular targeting of residual invading cells may
improve prognosis. The molecular biology of glioma invasion and potential therapeutic
anti-invasive targets are described in more detail below (please see "Molecular biology of
glioma invasion").

Chemotherapyfor glioblastoma
Chemotherapy is a component of standard glioblastoma treatment and modestly
improves 1 and 2 year survival by approximately 5%[227]. Alkylating agents are the most
commonly used chemotherapeutic agents used in the treatment of malignant gliomas which
induce DNA damage by covalently attaching an alkyl group to the

o6position of guanine.

Of these 1,3-bis(2-chloroethy1)-1-nitrosourea (BCNU) has been the most commonly used
since it was first described to improve survival when compared to patients who received no
chemotherapy and no radiotherapy[252]. Alternative methods of delivery to bypass the
blood-brain-barrier, such as BCNU-impregnated implantable polymers, are also employed,
and in certain subgroups of patients may improve surviva1[262].
Temozolamide (TMZ), a second generation imidazotetrazine pro-drug which is
physiologically converted to an alkylating agent, has a more favorable therapeutic profile
than BCNU and has become the chemotherapy agent of choice[l93]. TMZ, an oral agent,
crosses the blood-brain barrier and exhibits limited systemic toxicity. Furthermore, TMZ
improves progression-free survival by 13% at six months in patients with recurrent
glioblastoma[269]. When combined with radiotherapy, TMZ increases median survival
relative to radiotherapy alone[228]. The DNA repair enzyme 0 6 - m e t h y l g u a n i n e - ~ ~ ~
methyltransferase (MGMT) is primarily responsible for removal of alkyl groups from
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DNA and, therefore, is involved in resistance to alkylating agents in glioblastoma[l07].
Patients with methylation of the MGMT promoter, and subsequent silencing of the mgmt
gene, have a significant survival benefit from TMZ combined with radiotherapy relative to
those without methylation underscoring the importance of molecular characterization of
glioblastoma in optimizing treatment[79].

Radiotherapy for glioblastoma
In the treatment of glioblastoma, radiotherapy is used post-operatively in
combination with chemotherapy. Ionizing radiation induces DNA damage by directly
damaging the DNA molecule and indirectly by generating oxygen free radicals from water
molecules, which leads to apoptosis. While normal cells undergo apoptosis in response to
ionizing radiation, glioblastoma cells are notoriously resistant to apoptosis by molecular
mechanisms which will be described below[219]. Therefore, although escalating doses of
radiotherapy increase survival, radiotherapy is not curative[253]. Nevertheless, surgery
followed by radiotherapy improves survival when compared to surgery alone[252].
Current therapy consists of a total dose of 50 - 60 Gy in thirty 1.8 - 2.0 Gy fractions
targeting the entire enhancing tumor mass plus a 2 cm margin[l I]. In spite of numerous
large clinical trials, alternative delivery schedules, hyperthermia, particle therapy, and
radiosensitizers have not been shown to improve survival relative to conventional
fractionated radiotherapy[l20]. The majority of glioblastomas recur within 2 cm of the
original tumor site, in one study even after delivery of a 14 Gy boost to this area,
suggesting the presence of residual tumor cells near the resection cavity that are capable of
resisting apoptosis induced by adjuvant radiotherapy[56]. Therefore studies focused on
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improving the apoptotic response of residual tumor cells to radiotherapy become critical in
the search for a cure. Such in~provementsmay come from identification of molecular
changes in glioma that confer a resistant phenotype.
Glioblastoma molecular biology
The ability of glioblastoma cells to resist DNA damaging therapies suggests that
glioblastoma cells possess inherent resistance to DNA-damage induced cell death.
Specific molecular changes may explain this extreme resistance. In addition, molecular
mechanisms supporting cell invasion may allow tumor cells to disseminate widely enough
to evade surgical resection. Full molecular characterization of glioblastoma promises to
provide the basis for targeted molecular therapies that will complement the traditionally
employed modalities described above.
Glioblastoma can be divided into two subgroups based on clinical history; primary
and secondary glioblastoma. Cytogenetic and molecular examination of the two subgroups
of glioblastoma provides clues to central mechanisms underlying gliomagenesis and
glioblastoma behavior. Primary glioblastoma arises de novo without evidence of a less
malignant precursor tumor, occurs in older age groups, and is rapidly progressive with a
clinical history of less than three months. Secondary glioblastoma arises from a preexisting lower grade glioma, occurs in younger patients with the progression to grade IV
glioblastoma over 5 - 10 years. However, once diagnosis of glioblastoma is established,
the prognosis and histology of the tumors are indistinguishable. In addition to differences
in clinical history, these tumors can be distinguished by characteristic genetic
aberrations[258]. Primary glioblastoma possesses amplification of the receptor tyrosine
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kinase (RTK) epidermal growth factor receptor (EGFR)[258], murine double minute 2
(MDM2) amplification[21 I], mutation of the phosphatase PTEN[234], and deletion of
p161NK4a
[241]. Secondary glioblastoma is characterized by mutation of the p53 tumor
suppressor[258], loss of heterozygosity (LOH) on chromosome 10q[l19], and
overexpression of the RTK platelet-derived growth factor (PDGF) receptor and its ligand
PDGF[71]. Although the exact mutations are different between primary and secondary
glioblastoma, the pathways affected are similar; receptor tyrosine kinase-activated
pathways, and the tumor suppressor Rb- and p53-mediated pathways. As critical to both
primary and secondary glioblastoma, these pathways represent targets of action of
aberrantly expressed oncogenes in addition to being functional targets for novel
therapeutics.
Receptor tyrosine kinases
RTKs dimerize in response to ligand binding, undergo autophosphorylation, and
recruit adapter proteins which activate downstream effectors, such as the proto-oncogene
Ras. EGFR is amplified in approximately 40% of primary glioblastomas leading to
overexpression of the receptor[l25]. Of those that overexpress EGFR, 40% are termed
EGFRvIII and possess a deletion of exons 2 - 7 which encodes the extracellular ligand
binding domain, thus resulting in constitutive activation[86]. Activated EGFR, either by
ligand binding or activating mutations, stimulates downstream Ras/Raf/MEK/MAP kinase
and PI3 kinase/AKT signal transduction pathways, which are involved in cell proliferation,
survival, and invasion[97]. EGFRvIII increases the tumorigenicity of glioblastoma cells
both in vitro and in vivo, by increasing proliferation rate and decreasing apoptosis[l64].
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EGFRvIII expression also increases the chemoresistance of glioma cells[165]. Both of
these observations are associated with increases in the anti-apoptotic Bcl-2 family member,
Bcl-XL[165, 1641. Additionally, EGFRvIII increases the in vitro invasiveness of
glioblastoma cells, possibly due to up-regulation of several invasion related genes which
will be discussed in more detail below, including matrix metalloproteinases (MMPs) and
extracellular matrix (ECM) molecules(p1ease see "Molecular biology of glioma
invasionm)[l171. Specifically relevant to the treatment of glioblastoma, EGFR expression
strongly correlates with resistance to radiotherapy in a large clinical study[lO].
PDGFR and PDGF ligands are co-expressed in the same glioblastoma cells
suggesting an autocrine stimulatory loop[71]. Ligand binding to PDGFR activates the
same pathways as EGFR (i.e. MAPK and PI3K pathways) [218]. PDGF and PDGFR
overexpression represent early changes in glioma progression and therefore may play a
role in glioma development. In a large sample of low grade gliomas, PDGFR was
overexpressed in 50% and expression correlated with progression to high grade glioma
highlighting its role in secondary glioblastoma[247]. Mouse models provide clues as to
the function of PDGF in glioma progression. Artificial expression of PDGF in mouse
models induces the formation of oligodendrogliomas, however if AKT signaling is also
perturbed, astrocytomas form, underscoring the complexity of signaling pathways leading
to glioblastoma[36]. In addition to its role in glioma development, evidence indicates that
PDGF signaling continues to play a role in glioblastoma. Treatment of several
glioblastoma cell lines with specific PDGFR inhibitors decreased clonogenicity and tumor
growth in nude mice[l30]. PDGF signaling also contributes to glioma neovascularization,

13
an important component of glioblastoma tumorigenicity, by stimulating vascular
endothelial growth factor (VEGF) expression in tumor endothelial cells and subsequent
endothelial proliferation[72]. Therefore, PDGF not only has autocrine function, but also
paracrine action on tumor associated blood vessels. Most importantly, nude mice
harboring glioma xenografts respond to the orally active specific PDGFR tyrosine kinase
inhibitor, Gleevec (Imatinib) which is currently being used clinically to treat other types of
human cancers[lOl]. This has prompted a clinical trial to examine the efficacy of this
inhibitor in the treatment of glioblastoma. Although clearly important in gliomagenesis,
the mechanism of overexpression of PDGF is currently unknown.
Through either LOH on the long arm of chromosome 10 (secondary glioblastoma)
or mutation (primary glioblastoma), the phosphatase and tensin homology gene (PTEN) is
inactivated in the majority of malignant gliomas[l19,234]. PTEN is a 3' phosphoinositol
phosphatase that dephosphorylates PIP3, a second messenger involved in PI3KlAKT
signaling, thus acting as a negative regulator of the pathway. Loss of PTEN allows
constitutive activation of AKT leading to cell proliferation, survival, and development of
glioblastoma. Mutations in downstream effects of RTK represent alternative mechanisms
of stimulating tumor cell growth and resistance.

Retinoblastoma (RB) pathways
The gene encoding the tumor suppressor Rb is mutated in approximately 30% of
malignant gliomas[80]. Un-phosphorylated Rb binds E2F, inhibiting transcription of
genes involved in cell cycle progression. In response to growth promoting stimuli, Cyclin
Dl is activated which in turn activates cyclin-dependent kinase (CDK) 4 and 6, which
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phosphorylate Rb. Rb releases E2F which transactivates target genes leading to mitosis
and progression through the G1 checkpoint. The CDK inhibitor p161NK4A
inhibits CDK 4
and 6, preventing phosphorylation of Rb and maintaining cells in a quiescent state.
Inactivation of p1 6'NK4A
occurs in 50% of primary glioblastoma and represents an
alternative mechanism of inactivating the Rb tumor suppressor, leading to unregulated
growth[24 11.

p53 pathways
Mutations in the gene encoding the p53 tumor suppressor occur in 33% of human
glioblastomas and are more common in secondary glioblastoma. The most common
mutations in gliomas occur at codons 273,248, and 175 in order of decreasing
frequency[l2]. Tetramerization is required for wild-type p53 function which is attributed
to a C-terminal oligomerization domain. Therefore, mutant p53 can exert dominant
negative effects by oligomerizing with wild-type p53. Its tumor suppressor function is
intimately tied to its function as a transcription factor. DNA damage, including oncogenic
mutations, activates p53 which directly initiates cell cycle arrest and apoptosis by
transactivation of downstream target genes, most importantly the CDK inhibitor, p2 1WAF 1,
and the pro-apoptotic Bcl-2 family member, Bax, respectively[45, 1581. More recent
studies show that p53 is critical for autophagy, senescence, DNA repair, and
differentiation, all of which are consistent with tumor suppression[33, 65, 2711.
Normal cells possess low levels of p53 due to its short half life[5]. The ubiquitin
ligase MDM2 targets p53 for proteasomal mediated degradation and is the most important
mechanism of inactivation of p53[78]. As such, it is amplified in 13% of primary
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glioblastomas[211]. Interestingly, the same study showed that MDM2 amplifications are
mutually exclusive with p53 mutations suggesting it is one specific mechanism for
inactivating wild-type p53. Given the central role of p53 in tumor suppression and
sensitivity to DNA damaging therapies, glioma cells which possess wild-type p53 in the
absence of MDM2 amplification must harness alternative mechanisms of evading the p53
response.
As expected based on its role in response to DNA damage, p53 plays a key role in
response to radiotherapy. Adenoviral transduction of p53 mutant glioma cell lines with
wild-type p53 induces virtually 100% apoptosis within 4 - 8 days[68]. Stable transfection
of p53 into p53 mutant glioma cells decreases clonogenic survival after radiotherapy[66].

In vivo adenoviral transduction of mutant p53 gliosarcoma cells with wild-type p53 causes
reduction in tumor size and increased survival when combined with radiotherapy[8]. Proapoptotic downstream targets of p53 are critical to a successful apoptotic response to
radiotherapy. Wild-type p53 glioma cell resistance to radiotherapy demonstrated by lack
of ionizing radiation-induced apoptosis correlates with lack of Bax induction[2 191.
Adenoviral transduction of p53 mutant glioma cell lines with Bax increases sensitivity to
fractionated radiotherapy by inducing both in vitro apoptosis and in vivo tumor regression
in nude mice[6]. These results indicate that functional inactivation of wild-type p53 may
lead to a defect in Bax activation and therefore may explain glioma radioresistance.
In the response to radiotherapy, functional inactivation of p53 in glioma cells may
be achieved by decreased expression of Ataxia Telangiectasia Mutated (ATM), which
phosphorylates and activates p53 in response to DNA damage. In a study of a small
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sample of primary glioblastoma cultures, lower levels of ATM expression correlated with
increased clonogenic survival after irradiation[237]. Our laboratory has shown that
adenoviral transduction of glioma cells that possess wild-type p53 with additional wildtype p53 can decrease radioresistance suggesting the supraphysiologic levels of p53 can
overcome functional inactivation[l4]. A complete understanding of the mechanisms of
functional inactivation of p53 in glioblastoma promises to uncover novel therapeutic
targets to increase apoptosis and decrease resistance to radiotherapy.

Molecular biolog~of glioma invasion
In addition to increased proliferation and resistance to therapy, glioma cell invasion
is also a key component of tumorigenicity. The most provocative illustration of the
extreme invasiveness of glioma cells is the observation that these tumors recur even after
radical resections such as hemispherectomy of the affected cerebral hemisphere. This
underscores the concept that, even after wide margin resection of a glioblastoma, tumor
cells invading grossly normal appearing brain can cause recurrence and death[221]. It has
long been recognized that glioma cells preferentially invade along vascular basement
membranes in Virchow-Robins spaces, white matter tracts, and the subependymal zone
suggesting that factors, such as ECM components, present in defined areas of the brain
promote tumor cell migration[l42]. Glioma cell invasion requires a complex interaction
between the ECM and the cell. In point of fact, the first step in glioma invasion involves
adhesion of the cell to ECM components. Exposure of glioma cells to the ECM
components fibronectin, collagen IV, tenascin-C, vitronectin, and laminin stimulates
migration[l35, 621. In addition, glioma cells can modulate the ECM by secreting ECM
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components which can lead to increased adhesion ultimately enhancing invasion[63]. The
major cellular mediator of adhesion is the intergrin family which is comprised of
heterodimeric glycoproteins formed by various combinations of different a and P chains.
Up-regulation of pl integrin in C6 glioma cells causes diffuse invasion when implanted in
the brains of nude mice[186]. Conversely, in vitro invasion of glioma cells is blocked after
treatment with anti-pl antibodies[63]. The second step is cell movement which involves a
reorganization of the actin cytoskeleton resulting in a polarized cell with lamellopodia in
the invading front end and a retracting rear end[259].
The third step is invasion into an intercellular space created by the secretion of
ECM degrading proteases, in particular the MMPs. The MMPs are a multigene family
subdivided into groups based on their substrate specificity. Membrane type 1-MMP
(MT1-MMP), MMP-1, MMP-2, and MMP-9 are overexpressed in gliomas and are the
most well studied of the family[245, 146, 50, 1671. Levels of MMP activity increases with
increasing grade, being highest in glioblastoma, and may play a role in
aggressiveness[l67]. They are normally tightly regulated to maintain activity only when
needed for functions such as wound healing, angiogenesis, and axonal growth cone
extension. The MMPs are regulated at the transcriptional level and are often up-regulated
in response to growth factor stimulation[201]. Results from our laboratory show that a
single nucleotide polymorphism (SNP) in the MMP-1 promoter which creates a binding
site for ETS transcription factor family members leads to increased MMP-1 expression in
glioblastoma[l46]. The MMPs are secreted as inactive zymogens and require cleavage for
activation, thus introducing a second layer of regulation. Our laboratory has shown that
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EGF stimulation can cause up-regulation of MTl-MMP, which activates MMP-2 and
subsequently increases in vitro invasiveness[244]. MMP-2 and MTl -MMP are often
expressed in the same cell providing a mechanism by which the cell can directly activate
its secreted pro-MMP-2 by MTl -MMP in the cell membrane[50]. MMP-9 is expressed by
endothelial cells at the invading edge of glioblastoma and may be involved in the ingrowth
of oxygen supplying tumor vasculature into the rapidly growing tumor[50]. Third,
naturally occurring tissue inhibitors of MMPs (TIMPs) inhibit the enzymatic activity.
TIMP-1 expression is under-represented in glioblastoma suggesting a mechanism of
increased invasion[l67]. Transfection of a highly invasive glioma cell line that expresses
low endogenous levels of TIMPs with TIMP-1 causes a decrease in invasion[l43].
The concept behind adjuvant therapies following surgery such as radiotherapy and
chemotherapy impregnated wafers deposited in the tumor resection cavity is to target
residual invading tumor cells. Recent evidence suggests that certain characteristics of
invading cells may confer resistance to such therapies. DNA damaging therapies, such as
ionizing radiation and chemotherapy, target rapidly proliferating cells. However, glioma
cells selected for migration ability proliferate more slowly when plated on glioma-derived
ECM[147]. Decreased proliferation of invasive cells may be due to decreases in
expression of cell cycle regulatory proteins such as Cyclin A and B after exposure to ECM
proteins[l41]. Therefore, more slowly dividing invading cells may resist DNA damaging
therapies leading to regrowth and recurrence. Furthermore, glioma cells stimulated to
migrate by ECM components down-regulate pro-apoptotic genes while up-regulating antiapoptotic genes[l41]. Also relevant to choice of therapy is the surprising observation that
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inhibition of tumor angiogenesis with a monoclonal antibody against the VEGF receptor
decreased tumor growth but caused dramatically increased invasion of glioma cells along
host blood vessels eventually leading to leptomeningeal spread[ll2]. These results
demonstrate the interrelatedness of glioma molecular pathways and the importance of
understanding and targeting several pathways when treating malignant gliomas.

Wilms ' tumor 1 and glioblastoma
In search of novel genes involved in glioma biology, our laboratory performed
exploratory studies examining the expression of Wilms' tumor 1 (WT1) in glioblastoma
cell lines. We reported that 417 established glioma cells lines overexpressed WT 1[19 11.
Subsequently, we and several other groups demonstrated WT1 overexpression in larger
samples of glioma cells lines and glioblastoma tissue specimens[l52, 43, 178, 168, 301.
The function of WTl in these tumors is currently unknown. Evidence based on the known
physiologic and pathologic function of WTl which will be extensively discussed below
suggests many potential mechanisms of WTl function in glioblastoma.
Wilms' tumor
In 1899, Dr. Carl Max Wilms, a renowned German surgeon, comprehensively
reviewed childhood renal cancer in his book Die Mishgeschewulste der Niere. Due to his
thorough description of the disease and the correct assertion as to the cell of origin of the
tumor, the malignancy that he described, nephroblastoma, is now known as Wilms'
tumor[32]. Wilms' tumor, for which WTl is named, is the most common pediatric kidney
cancer with a median age at diagnosis of 3.5 years[l3]. Overall, it accounts for 6% of
pediatric malignancies[73]. The majority of Wilms' tumors are solitary, however 6% are
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bilateral and 12% are multifocal. Wilms' tumors metastasize to the lungs most commonly,
followed by the lymph nodes and liver, rarely to the bone and brain. Patients typically
present with an asymptomatic abdominal mass that is palpable on physical examination.
Current standard of care in North America involves nephrectomy followed by
chemotherapy with or without radiotherapy depending on the stage of disease[70]. In
contrast to GBM, survival has improved from 30% in the 1930's to greater than 85% in the
present day. Studies now focus on tailoring therapies to cure the disease while sparing the
patient from the side effects of systemic therapy.
Wilms' tumor 1 (WT1) structure and function
Knudson and Strong reviewed a large number of case studies and proposed a twohit model for Wilms' tumorigenesis, similar to that of retinoblastoma in which inactivation
of both alleles of a tumor suppressor gene were necessary for tumor formation[l06].
Cytogenetic analysis of individuals with WAGR syndrome (Wilms' tumor predisposition,
Aniridia, Genitourinary malformations, mental Retardation) implicated mutation in
chromosome 1 lp13 in the development of Wilms' tumor[53, 671. The region was also
observed to be mutated in sporadic Wilms' tumors, thus potentially harboring a tumor
suppressor[l08]. Subsequent examination of Wilms' tumor cell lines and embryonic tissue
led to the isolation of a transcript from this region[23, 591. This gene was shown to be
mutated in approximately 6% of sporadic Wilms' tumors and was named Wilms' tumor 1
(WT1)[59,246, 1261. As confirmatory evidence, WTl was found to be mutated in patients
with Denys-Drash syndrome, which consists of renal failure, pseudohermaphroditism, and
Wilms' tumor[187]. To date, WTl is the sole gene demonstrated to be involved in the
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development of Wilms' tumor. Several characteristics of WT1 biology suggest that it may
be important in glioblastoma behavior.
The wtl gene is composed of 10 exons approxin~ately50 kb in length and encodes
a 3.1 kb transcript[58, 231. Alternative splicing generates four major isoforms depending
on the inclusion or exclusion of 5 1 nucleotides encoded by exon 5 and nine nucleotides in
exon 9, known as KTS[75]. WT1 (+I+) contains both exon 5 and KTS, WT1(+I-) contains
exon 5 but lacks KTS, WT1(-I+) lacks exon 5 but contains KTS, and WTl(-I-) lacks both
exon 5 and KTS (Figure 1- 1).

Figure 1-1. Schematic representation of the four major protein isoforms of WT1 with
corresponding nomenclature. Gray boxes denote the two alternatively spliced exons;
exon 5 and KTS in exon 9.
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The WT1 protein has a molecular mass of 52 - 54 kDa, depending on the isoform[l62].
RNA editing converts uridine at the 839 position to cytosine, resulting in a change in
codon 280 from leucine to proline[216]. Translation from an in-frame CUG upstream of
the major WT1 start site generates novel 60 - 62 kDa WT1 isoforms[l8]. Translation
initiated at a downstream AUG generates N-terminally truncated WT1 isoforms of 36 - 38
kDa[208]. Both larger and smaller WT1 isoforms are expressed in human tissue and retain
transcriptional activity. Thus, the number of WT1 isoforms characterized is 24. Both
larger and smaller isoforms are expressed at lower levels and are less prevalent than the 4
major WT1 isoforms and are, therefore, less well studied[l8, 2081. Furthermore, studies
examining WT1 isoforms generated from the upstream CUG demonstrate that inclusion of
the extended N-terminus does not modify the function relative to the corresponding major
isoform[l8].
WTl is a transcription factor that contains an N-terminal proline and glutamine rich
region and four C-terminal Cys2-His2 zinc fingers[23, 591. The proline-glutamine-rich
region mediates homodimerization and transcriptional activation[l95,257]. Zinc fingers 2

- 4 share 6 1% homology with the early growth response- 1 (EGR- 1) transcription factor and
all four are involved in DNA binding[23, 1921. The zinc fingers also contain two nuclear
localization signals required for trafficking to the nucleus[l7]. As expected based on the
structural similarities, WT1 binds to the GC-rich EGR-1 consensus sequence[l92]. In
addition, WT1 binds to unique promoter sequences; TCC repeat motifs and a high affinity
binding site referred to as WTE[256, 1661. As would be expected of a transcription factor
involved in cancer development, WTl transcriptionally regulates the expression of several
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growth regulatory genes including the CDK inhibitorp21 WAF' and cyclin E[49, 1291. WT1
also up-regulates the expression of PDGF-A[255], which is of particular interest to
glioblastoma biology for reasons which have been outlined above. WT1 also represses
transcription of the anti-angiogenic factor, Thrombospondin-1 (TSP-1) in FR3T3
immortalized rat embryonic fibroblast cells[42]. In a separate study, antisense induced
WT1 knock-down caused decreased clonogenicity which was associated with upregulation of TSP-1 in HL-60 leukemia cells[198]. This also is potentially relevant to
glioblastoma because TSP- 1 expression in glioblastoma xenografts decreases growth rate
and vascularity[l09]. At the transcriptional level, WT1 may play a role in glioma biology
by modulating the cell cycle, growth factor-induced proliferation and survival, and
angiogenesis.
Alternative splicing of exon 9 inserts three amino acids, lysine-threonine-serine
(KTS), in the linker sequence between zinc fingers 3 and 4[75]. Nuclear magnetic
resonance analysis indicates that inclusion of KTS decreases the affinity of WTl for
DNA[l 151. This is explained by studies which show the increased length of the linker
caused by inclusion of KTS increases the flexibility between zinc fingers 3 and 4 that
prevents binding of zinc finger 4 to DNA[116]. However, these results were obtained
using only the EGRl consensus sequence to determine the stability of the WTIIDNA
complex[l15, 1161. Evidence suggests that WT1 (+KTS) recognizes unique motifs in gene
promoters[83].
In addition to functioning as a transcription factor, WTl(+KTS) isoforms may have
a unique function in post-transcriptional processing. Careful analysis of WTl localization
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in WT1 expressing mouse kidney cell lines and tissue demonstrate that WTl(+KTS) colocalizes in nuclear "speckles" with splicing factors, a pattern which is disrupted by
treatment with RNase A[121]. In the same study, WT1 co-immunoprecipitates with
antigens common to small nuclear ribonucleoprotein particles (snRNPs) which are
involved in mRNA splicing. More specifically, WTl(+KTS) is incorporated into
spliceosomes and physically interacts with the ubiquitous splicing factor U2AF65, which
is known to be present in nuclear speckles[100]. WTl also co-purifies with the poly(A)+
fraction of nuclear extracts from cell lines and fetal kidney tissue along with U2AF65 and
p116, another splicing factor[ll4]. Three-dimensional structural modeling comparing
WT1 with U1 A, a snRNP with known RNA recognition motif (RRM), identified a putative
RRM in the N-terminal region of WTl, however a functional significance of this model
has not been confirmed[lOO]. Recently, oligo(dT) chromatography to isolate RNPs
followed by Western and SD gel analysis identified WT1 in RNPs in two human leukemia
cell lines, for the first time suggesting that WTl may function in cancer by interacting with
both DNA as a transcription factor, and RNA at the post-transcriptional leve1[163]. The
mechanisms are currently unknown. To date, one RNA target of WT1 has been identified;
gel mobility shift assays demonstrate that WTl binds to exon 2 of IGF-2 RNA in an
interaction which requires the zinc finger region of WTl[24]. WT1 may therefore be one
of a limited number of genes that affect gene expression at the DNA and RNA level.

Regulation of WT1

Transcriptional regulation
Evidence suggests that the regulation of the WT1 gene is at the transcriptional
level. During nephrogenesis, WTl mRNA and protein are expressed at the same time. In
human cancers, there are rarely mutations in the wtl gene that could lead to its
upregulation (Table 1). While many studies have focused on the role of WTl in
tumorigenesis and organ development, relatively few have examined the regulation of the
WTl gene. However, six transcription factors have been described that may be directly
involved in WTl gene expression. PAX2, a transcription factor expressed at the same time
as WT1 during nephrogenesis, binds to the WT1 promoter as shown by EMSA and DNaseI
footprinting. Co-transfection of PAX2 caused upregulation of a WTl promoter reporter
construct[l45]. Furthermore, in breast cancer and acute myeloid leukemia (AML), PAX2
expression positively correlated with WT1 expression [222, 2201. Another paired box
transcription factor, PAX8, both endogenous and exogenous, can regulate the WT1
promoter as demonstrated by transient transfection experiments. Binding was
demonstrated by EMSA[52]. GATA-1, a transcription factor involved in hematopoeisis,
binds to an enhancer region in the WT1 gene and activates WT1 expression, shown by
EMSA and co-transfection with enhancerlpromoter-CAT reporter constructs,
respectively[263]. Furthermore, WT1 and GATA-1 mRNA are both expressed in
hematopoeitic cell lines and mouse spleens. Microarray analysis of MDA-MB-468 cells
transfected with a dominant negative Pea3 construct identified WTl as a potential target
gene of the ETS transcription factor family member. Transfection with Pea3 increased
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transcription of a reporter gene driven by the WTI promoter and increased WTI protein
expression. Recombinant Pea3 is also able to bind to ETS binding sites in the WTI
promoter as shown by EMSA[46]. Our laboratory has shown that several glioma cell lines
express Pea3 (McCready et al., unpublished data). Deletion studies of the WTl promoter
identified a putative Spl binding site as being involved in WT1 gene activation which was
confirmed by stable transfection experiments, EMSA, and Southwestern analysis. In the
same study, immunohistochemistry of the developing and adult rat kidney showed that Spl
is expressed in structures that express WT1[31]. Interestingly, hypoxia inducible factor-1

a (HIF-la) trans-activates the WTI promoter in cells exposed to hypoxia which leads to
increased survival[250]. This is potentially interesting for brain tumor research, in that
HIF-1 a expression and activity, particularly in response to intra-tumoral hypoxia, appear to
play a prominent role in the biology of high-grade gliomas[94]. However, our laboratory
has observed in vitro a decrease in WT1 mRNA expression in two WTI expressing
glioblastoma cells in response to 24 hours of hypoxia (Appendix 1).
Transient co-transfection studies in 293 transformed human fetal kidney cells show
that WTl (+I+) strongly represses the WT1 promoter, while WTl (-I+) is the weakest
repressor. WTI is one of the first genes to be shown to negatively autoregulate its own
expression by direct interaction of the protein with its promoter, as demonstrated by
EMSA[203]. Studies with 293 cells stably expressing an inducible WT1 (+I-) expression
vector confirmed this result[138]. Hypermethylation of CpG islands is another mechanism
of inhibiting the transcription of genes. The 5' promoter and intron 1 region as well as a 3'
enhancer region of the wtl gene contain several sites of methylation, and are methylated in
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several disease states including breast cancer and Wilms' tumor[l05, 123, 1401. In ovarian
cancer, WT1 expression significantly correlates with methylation status[98]. Furthermore,
in ovarian and breast cancer cells, treatment with a demethylating agent restores WT1
expression[98, 123, 1281. However, the clinical relevance of WT1 gene methylation is
questionable, as in breast cancer WTl is highly expressed regardless of methylation[l28].
In fact, in a large sample of human astrocytomas, WT1 was found to be hypermethylated,
while other studies have found WT1 to be overexpressed in astrocytic tumors[267].

Post-transcriptional regulation
Very little is known about the post-transcriptional regulation of WT1. WTl can be
phosphorylated by protein kinase A and C (PKA, PKC) at Serine residues 365 and 393,
which are located in the zinc finger 2 and 3 region of the protein[205, 2651.
Phosphorylation of WT1 inhibits its ability to bind DNA and its ability to repress the
PDGF-A promoter[205]. In addition, phosphorylation prevents WT1 binding to RNA and
leads to cytoplasmic retention of the protein[265]. The significance of phosphorylation in
human disease is unknown, however aberrant cytoplasmic localization of WT1 has been
observed in cancer, including glioblastoma[l78].

WT1 and development
Wilms' tumor arises from pluripotent embryonic precursor cells. The tumor is
composed of the three cell types derived from these precursor cells which are normally
present in kidney development; blastemal, stromal, and epithelial, and is therefore
classically described as "triphasicm[154]. In addition, the observation that WTl mutations
not only lead to Wilms' tumor development, but also to urogenital abnormalities supports a
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critical role for wild-type WT1 in normal development. The study of WT1 dysregulation
in Wilms' tumor has provided unique insight into the relationship between normal
development and tumorigenesis. During development, WT1 is expressed in two types of
tissues. One type is that undergoing mesenchymal to epithelial transition; the developing
kidney, spleen, adrenal glands, the mesothelial lining of the peritoneal, pleural, and
pericardial cavities, and the epithelial cells of the gonads[7, 191. The second is that of
ectodermal origin, namely defined regions of the brain and spinal cord[7]. In the adult,
WTl expression is restricted to the glomerular podocytes of the kidney and area postrema
in the brain[2 171.
Homozygous WTl mutant mice die early in gestation, possibly due to abnormal
formation of the mesothelial lining of the heart, lung, and abdominal organs[l 10, 1601.
Examination of the embryos revealed failure of kidney and gonad development which
correlated with an increase in apoptotic cells in the tissue[llO]. Lack of spleen
development in wtl-'- mice also demonstrated enhanced apoptosis in embryonic spleen
cells[81]. This suggests that WT1 may function in early development as a survival factor.
One potential mechanism for this effect could be by affecting the intrinsic apoptotic
pathway via Bcl-2, which contains a WTE site in its promoter. WTl transactivates the
anti-apoptotic gene encoding Bcl-2 which can protect cells against apoptosis-inducing
stimuli[l44]. This may also be relevant to the function of WT1 in cancer, as the same
study demonstrates that WTI levels correlate with Bcl-2 levels in a small sample of
Wilms' tumors. Bcl-2 is overexpressed in 33 - 70% of glioblastoma however no studies to
date have examined a correlation between WT1 and Bcl-2.
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In addition to the pro-survival function, WT1 may mediate epithelial branching in
the developing kidney. WTl trans-activates the amphiregulin gene, which encodes a
ligand for EGFR that is expressed concurrently with WT1 in the developing kidney and
that stimulates ureteric bud branching in mouse embryo kidney organ cultures[l24].
Amphiregulin expression has not been studied in glioblastoma, however it would be highly
relevant, given the established importance of EGFR signaling in the tumorigenicity of
glioblastoma. This is underscored by the observation that Amphiregulin is overexpressed
in hepatocellular carcinoma and contributes to the increased growth rate and resistance to
chemotherapy of these cancer cells[26].
Although the exact role of WTl in the development of the central nervous system
has not been studied, several studies suggest a role for WTl in neuronal differentiation.
Low levels of WT1 are expressed in the developing eye, specifically the retina[7,249].
WTl homozygous mutant mice have smaller eyes, thinner neuroretinas, and defective
optic nerves, associated with decreased proliferation and increased apoptosis of retinal
ganglion progenitor cells[249]. In vitro models of neuronal differentiation suggest
potential mechanistic roles for WTl in this process. Retinoblastoma cells, which are
malignantly transformed pluripotent retinal progenitor cells, can be induced to differentiate
into neurons, during which WT1 is downregulated[25 11. Furthermore, inhibition of WT1
expression in undifferentiated retinoblastoma cells partially blocks neuronal
differentiation, suggesting that WTl plays an important role in the early stages of neuronal
differentiation. Likewise, pheochromocytoma cells can be induced to differentiate into
neurons by treating with nerve growth factor (NGF), which is known to downregulate
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EGFR. This appears to be dependent on WT1 transcriptional regulation of the TCC
repeat-containing EGFR promoter, as WT1 expression is decreased with NGF treatment
and parallels the decrease in EGFR expression[l27]. The ability of WTl to up-regulate
EGFR is interesting, given the central importance of EGFR signaling to glioblastoma
behavior. In support of a role for WTl in neuronal differentiation, our laboratory has
shown that WTl expression is downregulated in human NTera2 teratocarcinoma cells
during retinoic acid-induced differentiation into neurons (Appendix B).

WT1 and cancer
Controversy exists surrounding the function of WT1 as a tumor suppressor or an
oncogene in tumorigenesis[l5 11. The expression of WT1 in human cancer specimens has
been extensively studied (Table 1-1).

Table 1-1. Major studies examining WTl expression in cancer
Cancer type

Detection method

Findings

References

Wilms' tumor

PCR, PCR-SSCP

81130 W T l mutations

Breast cancer

RT-PCR, Western blot,
sequencing

Leukemia

Northern blot, RTPCR, immuno,fluorescence

Pancreatic adeno

IHC

717 express WT1 mRNA, 27/31
express W T l protein, 0136
mutations
1511220 acute leukemias and
chronic leukemias in blast crisis
express W T l mRNA, 12/20
express W T l protein
30140 express W T l protein

Little et a/.,
199211261,
Varanasi et a/.,
199412461
Loeb et a/.,
2001 [ I 281, Oji et
a/., 200411751
Miwa et a/.,
1992[157],
Menssen et a/.,
199511531
Oji et a/.,2004[177]

Colorectal
adenoc

Real-time RT-PCR,
IHC, sequencing

Thyroid cancer

Real-time RT-PCR,
IHC, sequencing

Boneandsoft
tissue sarcoma

Real-time RT-PCR,
IHC, sequencing

Head and neck,
squamous

Real-time RT-PCR,
IHC, sequencing

Lung cancer

Real-time RT-PCR,
IHC, sequencing

Ovarian cancer

Northern blot, PCRSSCP
Real-time RT-PCR,
IHC
PCR-SSCP, IHC

Esophageal
cancer
Malignant
mesothelioma
Desmoplastic
small round cell
tumor
Retinoblastoma

20128 express WT1 mRNA, 41/46
express WT1 protein, 015
mutations
33/34 express W T l mRNA, 20121
express WT1 protein, 019
mutations
28/36 express W T l mRNA, 414
express W T l protein, 018
mutations
42/56 express W T l mRNA, 616
express W T l protein, 015
mutations
54/56 express W T l mRNA, 516
express W T l protein, 017
mutations
15/20 express W T l mRNA, 0120
mutations
12/12 express WT1 mRNA, 36/38
express W T l protein
No mutations, 54/56 express
W T l protein, 1/33 W T l mutation

RT-PCR, sequencing

416 rearrangement with fusion of
EWS and WT1 genes

RT-PCR, IHC

616 express WT1 mRNA and
protein
35146 express W T l mRNA, 71/76
express W T l protein

Oji et a/.,2003[179]
Oji et a/.,2003[176]
Ueda eta/.,
2003[240]
Oji et a/.,200311731
Oji et a/.,200211741
Bruening etal.,
19931161
Oji et a/.,2004[180]
Kumar-Singh et a/.,
1997111I ] , Park et
a/., 199311831
Gerald et a/.,
19951571

Wagner et a/.,
2002[251]
Malignant glioma
RT-PCR, real-time RTMenssen et a/.,
PCR, IHC
2000[152], Dennis
etal., 2002[43], Oji
et a/., 200411781,
Nakahara et a/.,
200411681
Abbrev., RT-PCR, reverse-transcriptase polymerase chain reaction; SSCP, single strand
comformational polymorphism; IHC, immunohistochemistry
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Although originally discovered as mutated in Wilms' tumor and classified as a tumor
suppressor, WTI mutations are relatively rare, occurring in a small percentage of Wilms'
tumors, leukemia, mesothelioma, and the rare desmoplastic small round cell tumor[126,
102, 1831. In contrast, wild-type WTl is overexpressed in breast cancer, acute leukemia,
colorectal cancer, lung cancer, ovarian cancer, head and neck squamous cell carcinoma,
and bone and soft tissue sarcomas[l28, 157, 179, 174, 16, 173,2401. As shown in Chapter
2 below, we have confirmed that overexpression of wild-type WT1 is present in
approximately 80% of glioblastomas, as well as 80% of grade 11 and I11 gliomas[30].
Multiple studies have examined the role of WT1 in leukemia. Wild-type WTI is
overexpressed in the majority of acute leukemia relative to normal bone marrow and
peripheral blood cells, indicating that WT1 is a reliable leukemia marker[l57, 153, 881.
WTI is also expressed in chronic leukemia in blast crisis, but is absent in chronic leukemia
in the chronic phase[] 57, 1.531. WTl is mutated in approximately 10-15% of leukemia,
primarily acute myelogenous leukemia[l02]. High WTI expression correlates with worse
prognosis in acute leukemia and can be used to predict the progression of myelodysplastic
syndrome to acute leukemia[90,23 I]. Furthermore, WTl levels in bone marrow and
peripheral blood after treatment are useful in the detection of minimal residual disease and
can help tailor additional therapies[90, 891. Clues to the function of WTI in leukemia
come from overexpression and inhibition studies. Transient transfection of wild-type WTI
into normal myeloid progenitor cells inhibits the differentiation of the cells, which is
significant in that differentiation arrest is characteristic of leukemia[91]. Overexpression
of WTI in a variety of human leukemia cell lines similarly causes a block in
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differentiation, thereby providing a potential role for WTl in leukemogenesis[229, 44,251.
The capacity of WTl to block differentiation is potentially clinically relevant, as high WT1
expression correlates with less differentiated samples in a large group of human
AML[185]. WTl expression can also protect leukemia cells from chemotherapeutic agents
by decreasing activity of the intrinsic apoptotic pathway which is associated with an
increase in anti-apoptotic Bak expression[93]. Simpson et al., provide further evidence for
a protective role of WTl in leukemia cell behavior by demonstrating that the anti-apoptotic
Bcl-2 family member A 1IBFL 1 is directly trans-activated by WT1[225]. When leukemia
cells expressing endogenous WTl are induced to differentiate, WTl is down-regulated
which is associated with a decrease in c-myc expression[215]. From a therapeutic
standpoint, WT1 downregulation by antisense oligonucleotides causes a decrease in
proliferation of leukemia cells which is accompanied by a decrease in viability and an
increase in apoptosis[3]. Additional studies show that apoptosis induced by WTl silencing
is associated with an increase in pro-apoptotic Bax expression[93]. WTl antisense
oligonucleotide treatment does not effect the viability of normal cells, suggesting the
potential for WTl as an attractive target for therapy[264].
Wild-type WT1 is overexpressed in the majority of breast cancer specimens
relative to normal breast tissue[l28]. WT1 protein is highly expressed in estrogen receptor
negative tumors which are more aggressive[223]. In a large clinical sample, real-time RTPCR analysis revealed that WT1 mRNA level is a significant prognostic factor as high
WT1 expression correlated with a significantly lower 5 year disease free survival[l59].
WT1 overexpression may be in part due to the RTK HER21neu which is overexpressed in
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aggressive breast cancers, as overexpression of HER21neu in breast cancer cells causes
upregulation of WTl expression and HER2Ineu inhibition decreases WTl
expression[239]. The same study also indicates the involvement of AKT which is
activated by HER2Ineu. WTl expression increases in breast cancer cells when treated with
growth stimulatory agents and, more importantly, antisense oligonucleotide-induced WTl
downregulation inhibits proliferation by inducing G1 arrest[239, 2701. The decrease in
proliferation is associated with decreased expression of cyclin D l , but the exact
mechanism is not known. All four WTl isoforms also trans-activate the c-myc protooncogene in breast cancer cells by directly stimulating the c-myc promoter[76]. Activation
of c-myc is known to stimulate proliferation, and therefore may provide an explanation for
the decrease in cancer cell proliferation after WTl downregulation. However proliferation
was not determined after WTl induced c-myc upregulation[76]. Nevertheless, this may be
relevant to glioblastoma biology as c-myc is overexpressed in tissue samples[236].
Decreased WTl expression also induces apoptosis in breast cancer cells which parallels a
decrease in the anti-apoptotic WTl target gene, Bcl-2[239]. The observation that WT1
represses the insulin-like growth factor-1 receptor (IGF-1 R), which acts as a survival factor
in cancer, adds complexity to the putative oncogenic function of WTl [I 971. The
mechanism involves WT1 interaction with the estrogen receptor. High levels of WT1
expression in breast cancer are associated with estrogen receptor negative tumors[223], so
the physiologic relevance of this observation is not known. Nevertheless, the exact role of
WTl in human cancer is exceedingly complex and to date not fully understood.
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WTl and invasion
The relationship between WTl and cell invasion has not been extensively studied.
A recent study, however, suggests that WTl may play a role in migration and invasion[95].
WTl overexpression in TYK ovarian cancer cells caused the cells to adopt a smaller size
and "fibroblast-like" morphology which was associated with decreased expression of aactinin 1 and cofilin, two cytoskeletal proteins. The expression of gelsolin, which is
involved in actin filament assembly, is upregulated in response to WT1 expression. WTl
overexpression also decreased focal adhesions, while increasing migration and invasion.
The phenotype could be reverted by forced expression of a-actinin 1 and cofilin, or
gelsolin silencing, suggesting that WTl may affect invasion by modulating cytoskeletal
structures. As described above, a-actinin 1 plays an important role in glioma invasion by
linking integrins to the actin cytoskeleton. Furthermore, the change in cell morphology
induced by WTl expression is similar to that adopted by the invading glioma cell.
Morphologically, glioma cells prone to invasion are small anaplastic cells[96, 601. In a
separate study, WTl was found to regulate the E-cadherin promoter, a cell adhesion
molecule involved in cancer cell invasion[85]. Given the characteristic invasiveness of
glioblastoma, the study of WTl and glioma cell invasion is warranted.

WTI andp53
As the debate rages over the function of WT1 as a tumor suppressor or oncogene, a
player of particular interest to glioma biology has arisen as a potential explanation: the
p53 tumor suppressor. In osteosarcoma cells and immortalized kidney cells, WTl and p53
co-immunoprecipitate demonstrating direct binding[l37]. Arguing for an oncogenic
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function of WT1, WTl inhibits p53 mediated apoptosis in addition to stabilizing the p53
protein[l36]. In large samples of female genital tract tumors and a small sample of Wilms'
tumors, WT1 expression strongly correlates with p53 expression[2, 1361. In endometrial
carcinoma, WT1 and p53 double positivity is associated with worse prognosis[47].
Unfortunately, none of these studies screened the p53 gene for mutations, which is crucial
for interpretation because of the stabilizing effect of WTl on p53. However, our
laboratory has shown that in a large sample of glioblastoma specimens, WTl expression
correlates with wild-type p53 (please see Chapter 2 and refl301). This may explain, in part,
the observation that 30% of glioblastomas overexpress p53 in the absence of stabilizing
mutations[202]. Furthermore, it may provide a partial mechanism for functional
inactivation of wild-type p53 in glioblastoma. It would be interesting to determine if WTl
expression and MDM2 amplification are mutually exclusive in glioblastoma, which would
suggest two pathways of functionally inactivating p53, however this study has yet to be
undertaken.
The reciprocal effect of the WTlIp53 interaction is exemplified by the dual
regulation of the insulin-like growth factor-I receptor (IGF-IR) promoter. The IGF-IR is
overexpressed in cancer and may function in malignant transformation by inhibiting
apoptosis[54]. WTl represses the IGF-IR promoter due to multiple WTl binding sites in
embryonic kidney cells and prostate cancer cells[261, 371. The decrease in IGF-IR
expression leads to decreased proliferation. Wild-type p53 also represses transcription of
the IGF-IR however this is not a consequence of direct binding to the promoter[260]. As
another consequence of their physical interaction discussed above, p53 inhibits the
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transcriptional repression activity of WTI at the IGF-IR[87]. This mechanism may be
more generalizable as reciprocal effects on transcriptional regulation due to WTlIp53
interaction have been documented in other studies[l37, 1361. An interesting side note is
that p53 increased the expression of WT1, a finding which requires follow-up[87]. It is
possible that one component of the tumor suppressive function of p53 is to act as a switch
which converts WTl to a repressor of oncogenes involved in transformation, such as the
IGF-IR. Potentially, in certain contexts, such as wild-type p53, WTI acts as a tumor
suppressor, while in others, such as the absence of p53, WT1 acts as an oncogene.
Conclusion

As a gene involved in the development and differentiation of the central nervous
system, in addition to its function as a regulator of several key glioma associated
molecules, WTI is in a unique position to be involved in both normal development and
gliomagenesis, when aberrantly re-activated. The ability of WT1 to modulate receptor
tyrosine kinase pathways, anti-apoptotic proteins, components of cell cycle regulation, cell
invasion, and the tumor suppressor p53 are of particular interest to glioma biology. More
extensive studies of the function of WTI in glioblastoma may prove WT1 to be critical to
gliomagenesis. Furthermore, WT1 targeting strategies may decrease the tumorigenicity of
glioma cells and potentially enhance other anti-glioma therapies, proving it to be a gene of
substantial clinical significance in neuro-oncology.
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Abstract

Object. Wilms' tumor 1 (WTl) is overexpressed in many types of human cancer.
Studies demonstrate that WTl promotes tumor cell proliferation and survival in some cell
lines by inhibiting p53-mediated apoptosis, however this relationship has not been studied
in gliomas.

Methods. We screened nine malignant glioma cell lines, fifty glioblastoma (GBM)
samples and sixteen lower grade glial tumors for WT1 expression. 519 cell lines, 44/50
GBM samples and 13/16 lower grade gliomas expressed WT1 mRNA by reverse
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transcriptase polymerase chain reaction (RT-PCR) analysis. WT1 expression was not
detected in normal astrocytes. Two WT1 isoforms, +/+ and -/+, were expressed by the
majority of these samples. Real-time PCR analysis of the GBM cell lines revealed that the
level of WT I mRNA ranged from 6.33 - 2 14.70 ng per ng 18s RNA. We screened the
GBM samples for p53 mutation by PCR and single-stranded conformational
polymorphism (PCR-SSCP) analysis and demonstrated an association between WTI
expression and p53 status. Tumors that contained wild-type p53 were significantly more
likely to express WTl than tumors that contained mutant p53.

Conclusions. The presence of WT1 in glioma cell lines and the majority of primary
tumor samples, and its absence in normal astrocytes, suggests that WTl expression is
important in glioma biology.

Introduction
Glioblastoma multiforme (GBM) is a WHO grade IV glial tumor that carries a
universally poor prognosis. Extremely resistant to both radiotherapy and chemotherapy,
the median survival is only one year. Unfortunately, it is also the most common primary
brain tumor[27]. Decades of intense research have determined that alterations in several
growth factors such as PDGF, EGF and their receptors, and tumor suppressors such as p53,
Rb, and PTEN are important to glioma biology[l34]. Despite these advances, a significant
clinical improvement has not been realized. Therefore, a more complete characterization
of the molecular changes in gliomagenesis is necessary to uncover potential markers and
targets for novel therapies. Previous studies examined the expression of the Wilms' tumor
1 (WT1) gene in human brain tumors, including gliomas, and found detectable expression
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in tumor cells, while normal cells expressed none[43, 152, 168, 1781. To date, no studies
have examined the WTl isoforms expressed by these tumors or the contribution of WTI to
prognosis and other clinicopathologic characteristics.
WTI was originally discovered as mutated in nephroblastoma, a common pediatric
kidney cancer also known as Wilms' tumor[23]. It was subsequently found that the wtl
gene, located at chromosome locus 1 1 ~ 1 3encodes
,
a 52-55 kD polypeptide containing
four C-terminal zinc fingers and an N-terminal transactivation domain[75]. The structure
is consistent with its known function as a transcription factor, and a large number of target
genes have been identified[l5 11. Furthermore, the message is alternatively spliced to
generate four main isoforms, designated +I+, -I+, +I-, -I-, depending on the inclusion or
exclusion of exon 5 and nine nucleotides in exon 9 known as KTS, respectively, which
may modulate the transcriptional activity of the protein[75]. WTl plays a major role in
normal development, most notably in the urogenital system, and is expressed in the
developing central nervous system[77,7].
Although originally classified as a tumor suppressor, WTl does not adhere to the
norn~alcharacteristics of such a gene. It is not ubiquitously expressed throughout the adult
body, nor is it commonly mutated in cancers[l9]. On the contrary, it is overexpressed in
many types of cancer, including breast carcinoma and acute leukemia. In both cases, high
levels of WTI expression detected by real-time PCR correlate with a worse prognosis
relative to those that express low levels of WTI [159, 901. Furthermore, inhibition of WTI
expression in human breast cancer and leukemia cell lines using antisense modalities leads
to differentiation, decreased proliferation, and increased sensitivity to treatment[270,229].
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Inactivation of the tumor suppressor p53 is a common aberration in human
malignant gliomas. p53 has well established functions in cell-cycle arrest and apoptosis
induced by DNA damage, as well as in DNA repair, senescence, and differentiation[248].
The p.53 gene is mutated in approximately 30% of GBM with the vast majority of these
mutations being point mutations located in exons 5-8[12]. Many treatments for glioma,
such as radio- and chemotherapy, cause DNA damage, and thus are likely to rely on p53
function for a therapeutic response[l33]. Alterations in other genes, such as mdm2, which
targets p53 for degradation, represent alternative means of inactivating p53 in
gliomas[l96]. In some cell types, WT1 inhibits p53-mediated apoptosis[l36].
In this study, we assessed a large sample of human glioma cell lines and glioma
specimens for WT1 isoform expression and p53 status, to determine if a correlation exists
between WT1 expression and prognosis, or p53 status. The majority of glioma cell lines
and specimens expressed the +KTS isoforms of WTl which correlated with the presence
of wild-type p53. These results suggest a critical role for WTl+KTS isoforms in glioma
biology, possibly through interaction with the tumor suppressor p53.
Clinical Materials and Methods
Cell culture and tissue preparation
Human glioma cell lines (U87-MG, T98G, U373, U118, LN18, LN229) were
obtained from American Type Culture Collection and were grown and passaged in
Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, glutamine, nonessential amino acids, and 1% penicillin-streptomycin in a humidified atmosphere of 5%
COz. LN-Z308 glioma cells, a kind gift from Dr. Erwin Van Meir, were maintained in the
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same conditions. VC95G and VC95T were derived in our laboratory from human
glioblastoma tissue and were maintained in the same conditions. Normal human astrocytes
(NHA) were obtained commercially from Clonetics (Cambrex Biosciences). PC3 prostate
carcinoma cells were used as a positive control for WT1 expression. For RNA extraction,
the cell lines were plated at a concentration of 1 X 1o6 cells1100 mm tissue culture dish and
allowed to attach overnight. Fresh frozen glioma specimens were selected from the VCU
Neuro-Oncology Tissue and Cell Culture Facility. The specimens were obtained in the
operating room, dissected from adventitial material, immediately snap frozen in liquid
nitrogen, and stored at -80" C in accordance with a protocol approved by the VCU
Institutional Review Board. Before RNA, DNA, or protein extraction, tissue was
homogenized using a -80" C mortar and pestle. Total RNA was isolated from tissue and
cell line samples using the Trizol extraction protocol (Invitrogen). DNA was isolated from
tissue using the QIAamp DNA Mini kit protocol (Qiagen). The concentration of RNA and
DNA was determined by spectrophotometry. Protein was extracted from cell lines using
SDS buffer (50 mM Tris-Cl, 1% SDS, 10% glycerol) supplemented with protease
inhibitors. Protein was extracted from tissue samples using the same extraction buffer
followed by sonication. The concentration of protein was determined by DC protein assay
(BioRad).

RT-PCR and sequencing
Reverse transcription was performed using the Superscript I1 RT-PCR system
(Invitrogen). A 10 pl sample of the RT reaction mixture was added to 40 p1 PCR mixture
containing PCR buffer, dNTP mixture, Platinum Taq DNA polymerase, primers, and
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MgC12 to a final concentration of 1.82 mM. The first set of amplifications utilized a 2 1mer 5'-GTT-ACA-GCA-CGG-TCA-CCT-TCG-3'
located in exon 2 and a 22-mer 5'-

CCT-GAA-TGC-CTC-TGA-AGA-CAC-C-3'
located in exon 6 (primer pair 1, Figure 2la). A separate set of amplifications was performed with a 22-mer 5'-GAC-GTG-TGCCTG-GAG-TAG-CCC-C-3', a primer located in exon 7 and a 21 -mer 5'-GCT-GCC-TGGGAC-ACT-GAA-CGG-3'' a primer located 17 bp upstream of the stop codon (primer pair
2, Figure 2-la). In a separate reaction, 2 p1 of RT reaction mixture was added to 48 p1 of a
similar PCR mixture to amplify a segment of GAPDH mRNA as a control. PCR products
were electrophoresed on ethidium bromide-stained 1% agarose gels. For sequencing, the
PCR product was extracted from gels using the QIAquick Gel Extraction Kit (Qiagen).
The extract was then sent to the Molecular Core of the Virginia Commonwealth
University-Massey Cancer Center Nucleic Acids Research Facilities for direct sequencing
to determine the KTS status of the mRNA.
Real-time PCR analysis
The experiments were performed in the ABI Prism@ 7900 Sequence Detection
System (Applied Biosystems) using the TaqMan@ One Step PCR Master Mix Reagents
Kit (P/N: 4309169). All the samples were tested in triplicate under the conditions
recommended by the fabricant. The cycling conditions were: 48OC/30min; 95°C/10min;
and 40 cycles of 95"C/15sec and 60°C/lmin. The cycle threshold was determined to
provide the optimal standard curve values (0.98 to 1.0). The probes and primers were
designed using the software Primer Express@ 2.0. The probes were labeled at the 5' end
with FAM (6-carboxyfluorescein) and at the 3' end with TAMRA (6-
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carboxytetramethylrhodamine). Ribosomal RNA (1 8 s rRNA) from the Pre-developed
TaqManBAssay Reagents (PIN: 43 10893E) was used as endogenous control. The
reactions and the synthesis of the probes and primers were performed in the VCU Nucleic
Acid Research Facilities.
Western blot analysis
For WTl protein analysis, 100 pg of total protein lysate was separated by SDSPAGE, transferred to nitrocellulose membrane, and the membrane blocked with 5% nonfat
milk solution for 1 hour at room temperature. Mouse anti-WT1 monoclonal antibody
(Dako) was diluted 1:200 in blocking buffer. The membranes were incubated with
primary antibodies overnight at 4°C. The membranes were washed six times in Tris
buffered saline containing 0.05% Tween-20 before and after a one hour incubation at room
temperature with horseradish peroxidase-conjugated anti-mouse secondary antibody
(Rockland, Inc.) at a dilution of 1:1000. Blots were developed using the ECL detection
System (Amersham Biosciences). Anti-Cyclophilin A monoclonal antibody (Upstate
Biotechnology) at a dilution of 1:1000 was used as a control for protein loading.
PCR-Single strand conformational polymorphism analysis
100 ng of genomic DNA was used as the template for PCR as described above.
Exons 5-8 of the human p53 gene were amplified from tumor DNA in 4 separate reactions
using primer pairs described previously[l88]. DNA extracted from blood samples
obtained from five normal controls was used as SSCP controls. The PCR products were
electrophoresed on a 7% acrylamide gel and visualized by silver staining. Bands which
differed from those in normal control blood were considered mutations.
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Statistical Analysis
WT1 expression was dichotomized as tumors expressing full-length WT1 versus
non-full-length, which included tumors not expressing WTl and those expressing
potentially truncated WT1. Similarly, p53 was dichotomized as wild-type versus mutant.
Thereafter, the relationship between WT1 and the categorical clinical variables (e.g., sex,
tumor location, and p53 status) of the GBM patients was first analyzed using Fisher's exact
test. For any variable found univariately to be significantly associated with WTl, a
logistic regression model was fit to estimate the odds ratio and associated 95% confidence
interval. The relationship between WT1 expression and the continuous variable age was
analyzed using a t-test. Survival was calculated from the date of diagnosis of GBM until
the date of death, censoring for patients still alive. Kaplan-Meier survival curves were
estimated for the WT1 full-length and non-full-length groups and were compared using the
log-rank test.
Results
Malignant glioma cell lines expressed WT1. We screened nine human malignant
glioma cell lines for WT1 expression by RT-PCR, first using primer pair 1 that spans the
exon 5 splice site (Figure 2-lb). Five glioma cell lines expressed detectable WT1 mRNA.
RT-PCR using primer pair 2 spanning the KTS splice site in exon 9 confirmed WT1
mRNA expression in the five cell lines and a lack of expression in normal human
astrocytes (Figure 2-lc). Sequencing of the PCR products revealed that the cell lines
expressed the +I+ and -I+ isoforms of WT1, with the exception of VC95G, which
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expressed the +/- and -1- isoforms. We quantified the level of WTl mRNA, relative to 18s
RNA, being expressed by the cell lines using real-time PCR (Figure 2-ld).

Figure 2-1. Human glioma cell lines express WT1 mRNA. A. Schematic
representation of the WT1 cDNA. Each exon is depicted as a separate numbered box.
Alternative splices are depicted as darkly shaded boxes. Primers and products are depicted
as arrows. Primer pair 1 spans the splice site in exon 5. The alternative splice in exon 9 is
designated KTS and is spanned by primer pair 2. B. Glioma cell line RNA extract was
analyzed by RT-PCR using primer pair 1. Numbered lanes correspond to the following
cell lines; (1) PC3 prostate carcinoma positive control, (2) NHA normal human astrocytes,
(3) U87MG, (4) VC95G, (5) VC95T, (6) T98G, (7) U373, (8) U118, (9) LN18, (lo)
LN229, (1 1) LN-Z308, (12) no RNA template control, (13) no cDNA template control. In
a separate reaction, detection of GAPDH was included as a control for RNA loading. C.
Glioma cell line RNA extract was analyzed by RT-PCR using primer pair 2. D. Levels of
WTl mRNA expression were determined by real-time PCR. WTl levels are shown as
ratios of ng WT1: ngl8S mRNA levels.

roo
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The real-time PCR confirmed the qualitative RT-PCR data, detecting WT1 mRNA in the
same lines by both assays. LN18 and T98G cell lines expressed relatively high levels of
WT1 mRNA, while VC95G, U118, and U373 expressed low levels. Sequencing and realtime PCR data are summarized in Table 2- 1

Table 2-1. Sequencing data demonstrating the specific isoforms and levels of
VVTl mRNA expressed by glioma cell lines per ng 18s RNA
Cell line

LN229

WT1 isoform*

Nd

ng WT1 I ng 18s

0.0 k 0.0

LN-Z308
Nd
0.0 & 0.0
*VVTl isoforms are designated (exon 5)/(KTS) or nd, not
detected
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To confirm WTl gene expression at the protein level, we performed western blotting on a
representative subset of the cell lines; U87-MG, T98G, LN18, and LN-Z308. Consistent
with the RT-PCR data, T98G and LN18 cells expressed WTl protein, while U87-MG and
LN-Z308 cells did not (Figure 2-2).

Figure 2-2. Western blot analysis of WT1 protein expression. 100 pg of protein
extracted from PC3 prostate carcinoma positive control, U87MG, T98G, LN-18, and LN2308 cell lines were analyzed by Western blotting using mouse anti-WT1 monoclonal
antibody (Dako). Blots were also probed with anti-cyclophilin A to demonstrate equal
protein loading. CypA, cyclophilin A.
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Glioblastoma multiforme specimens expressed WT1. Previous studies of small
samples of GBM tissue suggest that WTl expression is not clinically relevant and is only a
phenomenon caused by extended culture of glioma cells[43, 1521. We found that WTI
mRNA expression did not change with increasing passage number in established glioma
cell lines (data not shown). To confirm that a significant proportion of human malignant
gliomas expressed WTl, we screened fifty GBM specimens. The specimens contained >
80% tumor tissue relative to normal brain tissue as determined by pathologic analysis.
Twenty three (46%) of the samples were from female patients and the remaining twenty
seven (54%) were from male patients. The average age of the patients was 57.3 years.
Nine (1 8%) of the GBM samples were located in the frontal lobe, 11 (22%) in the parietal
lobe, 20 (40%) in the temporal lobe, 9 (1 8%) in the occipital lobe, and one (2%) in the
insular lobe. The patient population survived a median of 45 weeks after the diagnosis of
GBM. By RT-PCR, 44/50 (88%) of the specimens expressed WTl mRNA (Table 2-2).

Table 2-2. Summary table depicting the Wl expression and p53 mutaion status
of glioblastoma multiforme specimens and respective clinical information.
Pt #
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

Sex
F
F
M
M
M
F
M
M
F
F
F
F
M
M
F
F
M
M
M
F
F
F
F
F
M
M
M
F
M
F
F
M
M
M
M
F
F
M
F
M
F
F
M
M
M
M
M
M
F
M

Age
39
79
80
68
75
66
19
45
55
60
49
58
64
49
77
43
61
64
62
60
51
20
54
67
54
33
60
47
64
44
58
51
65
78
80
64
68
76
51
37
49
33
74
63
72
50
62
37
59
71

Location
Frontal
Occipital
Temporal
Occipital
Temporal
Occipital
Frontal
Occipital
lnsula
Parietal
Parietal
Parietal
Occipital
Temporal
Parietal
Temporal
Temporal
Frontal
Frontal
Temporal
Occipital
Temporal
Temporal
Occipital
Temporal
Frontal
Temporal
Parietal
Parietal
Frontal
Parietal
Parietal
Occipital
Parietal
Temporal
Temporal
Frontal
Parietal
Frontal
Temporal
Occipital
Parietal
Temporal
Temporal
Temporal
Frontal
Temporal
Temporal
Temporal
Temporal

WTl(exon 5)
nd
+,-exon 5
+,-exon5
+,-exon 5
+,exon 5
+,-exon 5
+,-exon5
+,-exon 5
+,exon 5
nd
+,-exon 5
+,-exon 5
+,-exon 5
nd
+,exon 5
+,exon 5
+,exon 5
+,exon 5
+,exon 5
+,-exon 5
+,-exon 5
+,-exon 5
+,exon 5
+,-exon 5
+,-exon 5
+,-exon 5
+,-exon 5
+,-exon 5
+,-exon 5
+,-exon 5
+,-exon 5
+,-exon 5
+,-exon 5
+,-exon 5
+,exon 5
+,exon 5
nd
nd
+,-exon 5
+,-exon 5
+,-exon 5
+,exon 5
nd
+,-exon 5
+,exon 5
+,exon 5
+,exon 5
+,-exon 5
+,exon 5
+,exon 5

WTl(KTS)
nd
+KTS
+KTS
nd
+KTS
+KTS
nd
nd
+KTS
nd
+KTS
+KTS
+KTS
nd
+KTS
+KTS
+KTS
+KTS
+KTS
+KTS
+KTS
+KTS
+ KTS
+KTS
+KTS
+KTS
nd
+KTS
+KTS
+KTS
+KTS
+KTS
+KTS
+KTS
+KTS
+KTS
nd
nd
+KTS
+KTS
+KTS
+KTS
nd
+KTS
+KTS
+KTS
+KTS
+KTS
+KTS
+KTS

P53
wild-type
wild-type
wild-type
wild-type
wild-type
wild-type
mutant
mutant
wild-type
mutant
mutant
wlld-type
wild-type
wild-type
wild-type
wild-type
wild-type
wild-type
wild-type
wild-type
wild-type
wild-type
wild-type
mutant
wild-type
wild-type
mutant
wild-type
wild-type
wild-type
mutant
wild-type
mutant
wild-type
wild-type
wild-type
mutant
wild-type
mutant
wild-type
wild-type
wild-type
wild-type
mutant
wild-type
wild-type
wild-type
mutant
wild-type
wild-type

Survival (w)
living
33
11
19
15
48
64
19
39
82
67
36
184
77
14
106
124
27
39
4
190
107
49
84
67
55
28
66
14
48
61
44
ltflu
8
29
88
15
5
20
10
102
45
52
45
25
13
77
29
85
63

Pt #, patient number, nd, not detected, Itflu, lost to follow-up, -,+exon 5
denotes presence of both - and +exon 5 isoforms.
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Forty samples expressed WTl detectable by both primer pairs. Similar to the cell line
isoform profile, all 40 expressed both the +/+ and -/+ isoforms of WT1. However, samples
# 4, 7, 8, and 27 expressed WT1 detectable only by primer pair 1. There was no

significant correlation between WTl expression and either sex (p = 0.31), age (p = 0.72),
or location (p = 0.81). Patients with tumors that expressed WTI survived for a shorter
time than those that did not express WT1 (45 weeks versus 52 weeks) but that trend did not
approach statistical significance (p = 0.87). To confirm that the samples that expressed
WTl mRNA expressed WTl protein, western blot analysis was performed on samples #
13, 18,2 1,28, 3 1, and 39, all of which expressed WTl mRNA. All of the samples tested
expressed detectable WT1 protein (data not shown).

WT1 expression was associated with p53 status. As WTl interacts with p53 and
in certain types of cancer correlates with p53 expression, we screened .the GBM samples
for p53 status[l37, 2,471. Using PCR-SSCP, we screened all 50 GBM samples for p53
mutations in exons 5-8 (Figure 2-3).

Figure 2-3. Representative SSCP analysis of exon 5 ofp53 gene. Normal control lanes
contain DNA extracted from 5 different patients without brain tumors. Lanes 1-9 contain
DNA extracted from GBM samples from patients 1-9. Mutations in samples 7 and 8 are
demonstrated as extra fractions compared to normal controls and are indicated by arrows.

normal control

1

2

3

4 5 6 7

8 9

We detected mutations in 12 samples (Table 2-2). The expression of wild-type p53 was
significantly associated with WT1 expression (p < 0.05, Table 2-3).

Table 2-3. WTl expression is associated with p53 mutation status as determined
by PCR-SSCP in human GBM specimens
WT1

~ 5 3

Full-length

Non full-length*

Total

Mutant

7

5

12

Total

40

10

50

*Non-full length includes putative truncated mutant WTl and lack of WT1
expression.
**Tumors with wild-type p53 are significantly more likely to express fulllength WTl than those with mutant p53 (odds ratio 4.714; 95% CI 1.069,
20.789)
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Logistic regression showed that tumors with wild-type p53 were significantly more likely
to express full-length WTl than those with mutant p53 (odds ratio 4.714; 95% confidence
interval 1.069,20.789).
Lower grade glial tumors expressed WT1. To assess the WTl expression
pattern in relation to glioma progression, we screened sixteen lower grade gliomas for
expression of WT1. 415 pilocytic astrocytomas, 111 low grade glioma, 414
oligodendrogliomas, 214 anaplastic astrocytomas, and 212 anaplastic oligodendrogliomas
expressed WT1 by RT-PCR analysis (Table 2-4).

Table 2-4. Summary table depicting the W l expression status of
lower grade glioma specimens
Dx Sex Age W l ( e x o n 5) W l ( K T S )
Pt #
51
PA
M
6
+,-exon 5
+KTS
52
PA
F
12
+,-exon 5
+KTS
53
PA
F
6
+exon 5
- KTS
54
PA
F
11
nd
nd
55
PA
F
1
+,-exon 5
+KTS
56
All
M
5
+exon 5
+KTS
57
011
M
35
+,-exon5
+KTS
58
011
M
31
+,-exon 5
+KTS
59
011
F
29
+,-exon5
+KTS
60
011
M
47
+,-exon 5
+KTS
61
AAIII M
63
+,-exon 5
+KTS
62
AAllI F
13
nd
nd
63
AAllI F
52
nd
nd
64
AAIII M
47
+,-exon 5
+KTS
65
AOlll M
50
+,-exon5
+KTS
66
AOlll M
36
+,-exon5
+KTS
Pt#, patient number, Dx, diagnosis, PA, pilocytic
astrocytoma, All, a s t r ~ c y t o ~011,
a , oligodendroglioma,
AAIII, anaplastic astrocytoma, AOlll, anaplastic
astrocytoma, nd, not detected, -,+exon 5 denotes
presence of both - and + exon 5 isoforms
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With the exception of one pilocytic astrocytoma (#53) which expressed the +I- isoform and
one low grade glioma which expressed the +I+ isoform only, all low grade tumors
analyzed expressed both +I+ and -I+ isoforms of WT1.
Discussion
Of the nine human malignant glioma cell lines and the large sample of human
GBM specimens we characterized, we demonstrated that the majority expressed WT1. All
of the tumor samples that expressed the +KTS isoforms, which are the most prevalent in
nature[75]. Four out of five cell lines that expressed WTI expressed the (+KTS) isoforms.
One cell line, VC95G, expressed only the (-KTS) isoforms of WTl, raising the possibility
of a change due to growth conditions in culture. Nevertheless, the fact that the isoforms
expressed by the majority of our glioma cell lines mirror those expressed in human
glioblastoma provides the potential for in vitro studies to examine the function of WTl in
this disease process. We also screened 16 lower grade glial tumors for WTI mRNA
expression of which 13 expressed WTl . Since a subset of GBM, the secondary GBM, is
thought to arise from preexisting lower grade gliomas[258], this finding suggests that
aberrant expression of WTl may be an early change in human gliomagenesis. This is
further supported by the observation that, with the exception of one pilocytic astrocytoma
specimen, the isoform expression profile of the lower grade gliomas mirrored that of
GBM. Normal astrocytes did not express WT1, a finding which was to be expected as
WTl, although expressed in restricted areas of the developing CNS, is not expressed in the
adult brain[7].
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WTl binds to the tumor suppressor p53, which inhibits p53-mediated
apoptosis[l36, 1371. More recent studies of WTlIp53 interactions reveal that the presence
of either wild-type or mutant p53 can modulate the transcriptional activity of WT1 on the
insulin-like growth factor-1 receptor promoter. This finding led the authors to propose that
the behavior of WTl as an oncogene or tumor suppressor may be dictated by the cellular
p53 status[87]. We detected mutations in 24% of the samples using PCR-SSCP, similar to
the p53 mutation rate described in the brain tumor literature[l2]. Previous studies show
that PCR-SSCP is both a sensitive and specific method of detecting p53 mutations[lO,
2321. However, this method does not detect the small proportion of mutations that exist
outside of the exon 5-8 "hot spot" as well as the few mutations that do not affect DNA
conformation[l2]. We demonstrated an association between WTl expression and p53
mutation status in GBM samples. Tumors that possess wild-type p53 are more likely to
express full-length WT1 than tumors possessing mutant p53. It is therefore possible that
WTl is interacting with wild-type p53, contributing to oncogenic activity by preventing
the cell cycle arrest and pro-apoptotic effects of p53. We have observed that silencing the
WT1 gene can decrease glioma cell proliferation and improve response to chemotherapy
and radiotherapy, results which are consistent with an oncogenic function of
WTl (unpublished data).
The majority of the tumor samples appeared to express wild-type WT1.
Sequencing of all 10 exons of WT1 would be necessary to definitively conclude that
mutations are absent. The detection of WT1 mRNA by primer pair 1 and not primer pair 2
in 4 GBM samples may indicate the expression of a truncated form of WT1. This
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phenomenon was not observed in any of the cell lines. Several such truncated forms of
WTl have been characterized in human disease, including cancers such as prostate cancer
and Wilms' tumor[40,212]. Previous studies of GBM did not detect any mutations in the
WTl gene. This is not surprising considering the frequency of mutation that we report
here is low (4150) and could have been overlooked in the studies which performed
mutational analyses[43]. Furthermore, we detected the putative mutation by reverse
transcriptase PCR using two primer pairs. Other studies have used either
immunohistochemistry or real-time PCR to detect WT1, which would not detect such
mutations[168, 1781. If confirmed to be expressed in these and other GBM samples, the
structure and function of such putative truncated forms of WTl will need to be examined
in future studies.
WT1 expression did not correlate with any of the examined clinicopathologic
characteristics of the patients, including survival. Patients with tumors that expressed
WTl appeared to have a lower median survival than those that did not express WT1.
However, this was not statistically significant. The fact that the majority of lower grade
tumors also expressed WT1 would fi~rthersuggest that WT1 expression is not a marker for
tumor grade. Survival after diagnosis of GBM is currently best predicted by clinical
markers of the patient, such as age, Karnofsky performance status, and extent of
resection[l18,99]

. In fact, recursive partitioning analyses (RPA) identified several risk

groups based on these markers to predict prognosis[l18,214]. Unfortunately, the analysis
of WT1 correlation with RPA groups would require a larger sample size than that included
in this study. To date, no genetic markers clearly predict survival. GBM is a genetically
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heterogeneous tumor, with many overlapping pathways apparently leading to a similar
clinical outcome[l56, 1311. Therefore, molecular changes such as EGFR

overexpression/amplification and p53 mutation, while having established functional
importance in glioma biology, do not correlate with prognosis[l99]. Nevertheless, our
study demonstrates that anti-WT1 therapy may be a promising prospect for future glioma
therapies. WT1 is expressed by over 80% of GBM specimens and does not appear to be
expressed by normal cells. When expressed by GBM cells, WT1 is restricted to two
isoforms and, therefore, provides an attractive target. In glioma progression, WTl appears
to be expressed early and may therefore be a target for early treatment before the
development of GBM. In vitro and in vivo studies show that anti-WT1 immunotherapy
can cause lysis of WT1 expressing tumor cells and rejection of tumor challenge while
leaving normal WTl expressing cells and tissue undamaged[l72, 1821. Recently a phase I
clinical study demonstrated that anti-WTl immunotherapy is well tolerated and efficacious
in patients with leukemia and solid tumors[l81]. GBM is a tumor for which there is no
effective treatment. Surgery combined with radiotherapy can improve survival by months,
while chemotherapy adds a modest benefit[227]. Full characterization of WTl expression
in tumors such as GBM may establish WTl as a target for novel therapies.
Conclusions

The results of this study are consistent with an oncogenic function for WT1 in
human cancer, possibly by interacting with the p53 tumor suppressor. We believe that
WT1 expression is an aberration of normal astrocyte gene expression and is critical to
gliomagenesis. Furthermore, the presence of WTl expression in a high percentage of
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gliomas and its absence in normal astrocytes suggests that WTI may be a valuable marker
for gliomas as well as a potential molecular target for this currently incurable disease. This
study further argues for continuing efforts to determine the role of WTl in gliomagenesis.
Future studies will focus on the function of WTl+KTS isoforms in human gliomas,
specifically in relation to p53.
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Abstract
The Wilms' tumor 1 gene is overexpressed in human glioblastoma and correlates
with wild-type p53 status. In other cell types, WT1 inhibits p53-mediated apoptosis in
response to DNA damaging agents. However, neither this interaction nor the relationship
between WT1 and radiosensitivity has been studied in glioblastoma. To study this
interaction, we generated LN-229 glioma cell lines (p53 mutant) stably expressing WTI
isoforms and induced apoptosis by transfecting with different doses of wild-type p53
plasmid expression vector. Constitutive expression of WTl did not protect against
exogenous p53-mediated apoptosis. Likewise, WT1 expression did not protect against
72
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endogenous p53-mediated cell death induced by radiotherapy in U87MG cells, which
contain functional wild-type p53. We then tested the efficacy of WTl siRNA in inhibiting
WTl expression and its effect on radiosensitivity. In T98G and LN-18 glioma cells, which
possess p53 mutations, WTl siRNA decreased WTl protein to almost undetectable levels
by 96 hours post-transfection. Furthermore, WTl siRNA transfection caused a
significantly larger decrease in viability following irradiation than was seen in
untransfected cells in both cell lines after treatment with EDso of ionizing radiation. In
conclusion, WTl overexpression did not protect against p53-mediated apoptosis or
ionizing radiation induced cell death. WTl siRNA increased the radiosensitivity of two
human glioma cell lines independently of p53. Anti-WT1 strategies may, therefore, prove
useful in improving the response of glioblastoma to radiotherapy, thus potentially
improving patient survival.
Introduction
Glioblastoma multiforme (GBM) is a WHO grade IV glial tumor that carries a
universally poor prognosis with a median survival of approximately one year after
diagnosis[27]. Following surgery or biopsy, radiotherapy, often in conjunction with
adjuvant chemotherapy, modestly improves survival, however glioma cell resistance to
radiotherapy remains a major obstacle [253,224,252]. Decades of intense research have
identified several molecular mechanisms of glioma cell radioresistance[74,28]. Despite
these advances, a significant clinical improvement has not been realized. Therefore, a
more complete characterization of the molecular mechanisms of resistance is necessary to
uncover targets for novel therapies. Previous studies by our laboratory and others have
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examined the expression of the Wilms' tumor 1 (WT1) gene in human brain tumors,
including gliomas of all grades, and have found detectable expression in tumor cells but
not in normal cells, suggesting an important role for WT1 in glioma biology[30, 152,43,
168, 1781. However no studies to date demonstrate a relationship between WTl and
resistance to commonly administered therapies in gliomas.
WTl was originally discovered as mutated in nephroblastoma, a common pediatric
kidney cancer also known as Wilms' tumor[23]. It was subsequently found that the wtl
gene, located at chromosome locus 1lp13, encodes a 52-55 kD polypeptide, the structural
homology and function of which designate it as a zinc finger transcription factor[75].
Furthermore, .the messenger RNA transcript is alternatively spliced to generate four main
isoforms, designated +I+, -I+, +I-, -I-, depending on the inclusion or exclusion of exon 5
and nine nucleotides in exon 9 known as KTS, respectively[75]. WTl(+KTS) isoforms,
which gliomas express[30], may be involved in RNA processing in addition to having both
overlapping and unique transcriptional properties relative to WTl(-KTS) isoforms[38, 831.
The functional significance of exon 5 is less well understood, but may affect its interaction
with other proteins[200]. Although originally classified as a tumor suppressor, WT1 was
later found to be overexpressed in many types of cancer, including breast carcinoma and
acute leukemia, suggesting an oncogenic function for the gene[90, 1591. In fact, inhibition
of WTl expression in human breast cancer and leukemia cell lines using antisense
modalities leads to differentiation, decreased proliferation, and increased sensitivity to
treatment[229, 2701.
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One possible mechanism by which WTI could exert a tumorigenic effect in glioma
cells is through an interaction with p53. Inactivation of the tumor suppressor p53 is a
common aberration in human glioma progression[l2]. p53 causes cell-cycle arrest and
apoptosis in response to DNA damage[248]. Many treatments for glioma, such as radioand chemotherapy, cause DNA damage, and thus are likely to rely on p53 function for a
therapeutic response[l33, 101. While the effect of p53 mutation on glioma response to
radiation is uncertain, p53 status has prognostic significance in other malignant
tumors[230,4]. In cultured glioblastoma cells, p53 mutation promotes
radioresistance[266, 741. Studies by our laboratory and others show that introduction of
wild-type p53 into glioma cells using various transduction methods increases
radiosensitivity both in vitro and in vivo[l4, 8, 66, 341. Alterations in other genes, such as

mdm2, which targets p53 for degradation, represent alternative means of inactivating p53
in gliomas[211]. In Saos-2 osteosarcoma cells (p53 null), WT1 inhibits p53-mediated
apoptosis induced by overexpression of wild-type p53, chemotherapy, and radiation[l36].
We recently reported ,that, in a large sample of glioblastoma tissue specimens, WTl
expression correlates with the presence of wild-type p53[30].
This prompted us to examine if a functional relationship exists between WT1 and
p53 in the context of glioma radiosensitivity. In this study, we investigated the effect of
both WT1 overexpression and WTl silencing 011 p53-mediated cell death and on response
to radiotherapy. We found that, while WT1 overexpression does not protect glioma cells
against p53 mediated apoptosis or radiation-induced cell death, WT1 silencing sensitizes
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glioma cells to radiation-induced arrest and death. These results suggest that WTl may be
a potential target to improve the response of glioblastoma to radiotherapy.
Materials and Methods

Cell culture and tissue preparation
The p53 status of the glioma cell lines used in this study has been previously
determined (Table 3-1)[92], and confirmed in our laboratory by RT-PCR and cDNA

Table 3-1. Wl and p53 status of the glioblastoma cell lines used in this study
Cell line

p53 status (codon)[92]

WT1 mRNA / 18S[30]

U87MG

wild-type

OkO

T98G

mutant (237, Met-lle)

LN-18

mutant (238, Cys-Ser)

LN-229

mutant (98, Pro-Lys)

103.61 k 7.9
214.70

+ 20.9

0k0
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LN-229, U87MG, LN-18, and T98G human glioma cells were obtained from American
Type Culture Collection and were grown and passaged in Dulbecco's modified Eagle's
medium (DMEM) containing 10% fetal bovine serum, glutamine, non-essential amino
acids, and 1% penicillin-streptomycin in a humidified atmosphere of 5% C02. Total RNA
was isolated from cell lines using the Trizol extraction protocol (Invitrogen). The
concentration of RNA was determined by spectrophotometry. Protein was extracted from
cell lines using SDS buffer (50 mM Tris-C1, 1% SDS, 10% glycerol) supplemented with
protease inhibitors. The concentration of protein was determined by DC protein assay
(Bio Rad).

Plasmid construction and transient transfection
WT1 expression plasmids (in pcDNA3, Invitrogen) containing either WTI(+/+) or
WTI(-/+) isoforms were kindly provided by Dr. Charles T. Roberts, Jr. and have been
described previously[87]. Expression plasmids containing wild-type p53 (in pHCMVNeo-Bam) were kindly provided by Dr. Sumitra Deb and have also been previously
described[39]. Cells were plated in triplicate at a density of 2 X lo5 in six well plates and
allowed to attach overnight in DMEM without penicillin/streptomycin. Cells were
transfected with a mixture of 3 p1 Lipofectamine 2000 (Invitrogen) and plasmid diluted in
500 p1 DMEM without fetal bovine serum or penicillin-streptomycin and incubated for 4
hours at 37" C. After 4 hours, cells were supplemented with 1.5 ml DMEM with 10% fetal
bovine serum without penicillin-streptomycin. Twenty four hours after transfection, the
conditioned media was removed and replaced with 2.0 ml fresh DMEM with 10% fetal
bovine serum without penicillin/streptomycin.
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Short interfering RNA transfection
Transfections with WT1 siRNA were carried out using the pre-designed
siGENOME SMARTpool containing 4 siRNA sequences directed against WTl
(Dharmacon). A pool of 4 non-targeting siRNA sequences (siCONTROL Non-Targeting
Pool, Dharmacon) was used as a control and will be referred to as siscramble. Cells were
plated at a density of 2.5 X lo5 cells in six well plates and allowed to attach overnight.
Cells were then transfected using Oligofectamine (Invitrogen) diluted in 1 ml l x OptiMEM Reduced Serum Medium (Invitrogen) supplemented with 1% penicillin1
strepton~ycin.After a 4 hour incubation at 37OC, 500 pL of 3x FBSIOpti-MEM solution
was added to each well. The final siRNA concentration was 100nM. 24 hours after
transfection, cells were trypsinized, resuspended in fresh media, and either lysed for
protein1RNA extraction or re-plated for clonogenic cell survival assays and luminescent
cell viability assays.

Generation of stable transfectants
LN-229 and U87MG cells were plated at a density of 2 X 1o5 in six well plates and
allowed to attach overnight. Cells were transfected with 1.0 pg WT1 isoform expression
vectors as described above for transient transfection. Forty eight hours after transfection,
cells were selected in DMEM containing 600 pglml Geneticin (Invitrogen) for LN229 and
200 pglml for U87MG. Selection media was exchanged every 4 days.

Irradiation
Forty eight hours after siRNA transfection or after generation of stable
transfectants, cells were treated at room temperature with y-irradiation using a Cesiumsource Mark I Irradiator (Cs- 137,4.149Gy/min) at indicated doses.

Western blot analysis
For protein analysis of cells transfected with WTl, 10 pg of total protein lysate
were separated by SDS-PAGE and transferred to nitrocellulose membrane as per
manufacturers' protocol (Invitrogen). The membrane was then blocked with 5% nonfat
milk solution for 1 hour at room temperature. Rabbit anti-WT1 polyclonal antibody (1 :200
dilution, C- 19, Santa Cruz Biotechnology), mouse anti-p53 monoclonal antibody (1 :1000,
Ab-6, Oncogene Research Products), and mouse anti-p21 monoclonal antibody (1 :200,
DakoCytomation) were diluted in blocking buffer. The membranes were incubated with
primary antibodies overnight at 4°C. The membranes were washed six times in Tris
buffered saline containing 0.05% Tween-20 before and after a one hour incubation at room
temperature with horseradish peroxidase-conjugated anti-rabbit secondary antibody
(1 :1000, Rockland, Inc.) for WTl, and anti-mouse secondary antibody (1 :2000, Rockland,
Inc.) for p53 and p21. Blots were developed using the ECL Detection System (Amersham
Biosciences). Anti-Cyclophilin A monoclonal antibody (1 :1000, Upstate Biotechnology)
was used as a control for protein loading.

Trypan blue exclusion viability assay
After treatment, cells were gently trypsinized from the culture surface, centrifuged,
and the cell pellet resuspended in 1 ml of DMEM. A 1:5 dilution of cells was made with a
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solution containing 30 yl 0.4% trypan blue in a total volume of 100yl. Viable cells, which
had excluded the dye, were counted by light microscopy. All treatments were performed
in triplicate.

Luminescent viability assay
Cells were plated in 5 - 10 replicates per treatment group in white 96 well plates at
a density of 1000 cells. At the specified time after treatment, CellTiter-Glo Luminescent
Cell Viability Assay (Promega) was performed according to the protocol supplied by the
manufacturer. Luminescence was detected by Lumi Star Luminometer (BMG). Percent
survival was calculated by taking the relative luminescence unit of each irradiated replicate
of a treatment group and dividing it by the average of the corresponding non-irradiated
treatment group.

Detection of apoptosis
After treatment, cells were trypsinized, washed with PBS, and fixed for 30 minutes
in 1% paraformaldehyde at a concentration of 1-2 X 1o6 cells/ml. Prior to analysis, fixed
cells were stored at 4" C in 70% ethanol. DNA cleavage was used as an indicator of
apoptosis. Treated cells were subjected TUNEL (APO-DIRECT, BD Biosciences)
followed by flow cytometry (FACScanto, BD Biosciences) to detect strand breaks.
Threshold level for forward scatter was set to exclude cellular debris and TUNEL-positive
cells were measured in the FL-2 channel (FITC).

Clonogenic survival assay
Following siRNA transfection, 1 X 1o2 LN- 18 cells were plated in triplicate in six
well plates. Plates were irradiated 48 hours after transfection as described above. Eight
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days after irradiation, cells were fixed for 30 minutes in methanol and stained with 50%
Giemsa for one hour. Cells were then washed with distilled water and colonies consisting
of 2 50 cells were counted.

Statistical analysis
Differences between multiple treatment groups were analyzed by analysis of
variance (ANOVA) using the JMPIN 4.0.4 (SAS Institute, Inc.) software. Tukey- Kramer
honestly significant difference test (HSD) was performed as a post-hoc analysis.
Differences between only two treatment groups were analyzed by Student's t-test.
Results

LN-229 glioma cells undergo apoptosis in response to p53 overexpression. To
examine the functional relationship between WTl and p53, we developed a glioma cell
model of p53 mediated apoptosis. LN-229 glioma cells do not express endogenous
WTl[30] and harbor a p53 mutation. Transfection of LN-229 cells with increasing
amounts of wild-type p53 expression vector led to an increase in p53 protein expression
and a concomitant up-regulation of the p53 target gene, p21, indicating that the exogenous
wild-type p53 is functional (Figure 3-1A). Increasing amounts of wild-type p53
expression vector resulted in a decrease in cell viability relative to cells transfected with
the empty vector, which was maximal at a dose of 0.1 pg, and still present at 0.04 pg
(Figure 3-1B). The decrease in viability of cells transfected with p53 relative to empty
vector was most prominent at 4 days after transfection (Figure 3-1 C). Based on the above
results, we chose to focus the subsequent experiments on the 0.1 pg p53 treatment dose,
and to examine viability at four days after transfection. To determine if the cell death
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induced by p53 was due to apoptosis, LN-229 cells were transfected with 0.1 pg p53 and
subjected to to terminal deoxynucleotidyltransferase-mediated deoxyuridine triphosphate
nick end-labeling (TUNEL) analysis to detect DNA cleavage which is a hallmark feature
of apoptosis. Untransfected control and cells transfected with vector alone exhibited
minimal DNA cleavage (1.8 and 1.7 %, respectively, Figure 1D). There was a significant
increase in TUNEL positive cells after p53 transfection (1 0.5 %, p = 0.007, Figure 3-1 D).
This suggests that LN-229 underwent increased apoptosis in response to transient p53
expression.

Figure 3-1. Transient transfection of p53 in LN-229 human glioblastoma cells. A.
LN-229 cells were transfected with increasing doses of p53 plasmid. Protein was extracted
24 hours after transfection. Western blot demonstrated p53 protein expression and upregulation of the p53 target gene, p21. Anti-cyclophilin A was used to estimate equal
protein loading. B. LN-229 cells were transfected with increasing amounts of p53
plasmid. Four days after transfection, cells were trypsinized and analyzed for cell viability
by trypan blue exclusion assay. All treatments were performed in triplicate. C. LN-229
cells were transfected with 0.1 pg p53 plasmid. Cells were trypsinized at 1,2,4, and 6
days after transfection and analyzed by trypan blue exclusion assay. All treatments were
performed in triplicate. D. LN-229 cells were transfected with 0.1 pg p53. Four days
after transfection cells were subjected to TUNEL. Cells were then analyzed by FACS to
detect DNA cleavage indicative of apoptosis (X-axis, FITC). Anotated numbers represent
percentage of cells positive for apoptosis. The graphs are respresentative of treatments
performed in triplicate. The experiment was repeated with similar results. Left panel,
LN229 untransfected control; middle panel, LN229 + empty vector; right panel, LN229
+p53, CypA cyclophilin A; VC vector control.

ug plasmid

days
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Stable expression of WT1 isoforms does not protect LN-229 cells from p53induced cell death. Using a liposomal delivery system, we generated pooled LN-229
stable transfectants expressing either empty pcDNA3 vector or pcDNA3 containing
WTl(+/+) or WT1(-/+) isoforrns, which are the isoforms expressed in human glioblastoma.
These cells were named LN229.VC, LN229.+/+, and LN229.-/+, respectively. After
maintenance for several months in selection media, the cell lines were analyzed for WTl
isoform expression by western blot. LN229.VC did not express detectable WT1 protein,
while LN229.+/+ expressed a 55 kDa protein corresponding to higher molecular weight
WTl(+/+) relative to LN229.-/+ which expressed the 52 kDa WT1(-/+) protein (Figure 32A and C, lanes 1, 3, and 5). To test the effect of WT1 expression on p53-mediated
apoptosis, the cell lines were transfected with either empty vector or wild-type p53 at doses
of both 0.1 pg and 0.04 pg. Cells transfected with empty vector expressed baseline levels
of p53 protein which is expected as p53 mutations cause stabilization of the protein[5]
(Figure 3-2A and C, lanes 1,3, and 5). Cells transfected with p53 expressed very high
levels of p53 and showed up-regulation of p21 (Figure 3-2A and C, lanes 2,4, and 6).
Four days after transfection, there was no difference in percent viability between the stable
cell lines after transient p53 expression determined by trypan blue exclusion at either the
0.1 pg or 0.04 pg dose (p = 0.19 and 0.67, respectively, Figure 3-2C and D).

Figure 3-2. Effect of transient p53 expression in LN-229 cells stably transfected with
WT1 isoforms. LN-229 cells expressed p53 and p21 after transfection with 0.1 pg (A)
and 0.04 pg (C) p53 plasmid. Blots were reprobed with anti-cylcophilin A to control for
equal protein loading. Trypan blue exclusion assay depicting the change in % viability
after transfection with 0.1 pg (B) or 0.04 pg (D) p53 plasmid. Y axis depicts change in
viability between cells transfected with p53 and cells transfected with empty vector.
LN229.VC, LN229 cells stably expressing empty vector; LN229.+/+, LN229 cells stably
expressing WT1 (+I+) isoform; LN229.4, LN229 cells stably expressing WTl (-I+)
isoform Error bars represent the standard error (B) or standard deviation (D). VC, vector
control; CypA, cyclophilin A.
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Stable expression of WT1 isoforms does not protect against radiation induced cell
death. We then tested the effect of WTl expression on an endogenous p53 response.
U87MG cells have wild-type p53 status and undergo functional p53 signaling pathways
following treatment with ionizing radiation[92, 2541. U87MG cells also do not express
WT1[30]. We generated pooled U87MG cell lines stably expressing either empty vector,
WTl(+/+), or WTl(-I+), referred to as U87.VC, U87.+/+, and U87.-/+, respectively.
Western blot showed that U87.VC did not express detectable WTl protein, while U87.+/+
and U87.-/+ expressed WTl isoforms of their corresponding molecular weights (Figure 33A, top panel, lanes 1,3, and 5). Twenty four hours after exposure of the cells to 6 Gy of
ionizing radiation, there was detectable up-regulation of p53 protein relative to nonirradiated cells (Figure 3-3A, bottom panel). Irradiation caused a time dependent decrease
in viability of the U87MG cells reaching 45% relative to non-irradiated cells at 7 days after
treatment, however stable expression of WTl did not cause a change in percent viability
(Figure 3-3B). The experiment was repeated 3 times at the 7 day time point with similar
results (Figure 3-3C).

Figure 3-3. Effect of ionizing radiation on U87MG cells, which express wild-type p53,
stably transfected with WT1 isoforms. A. U87MG cells were transfected with
expression plasmids containing WT1 isoforms, and selected for stable expression. Pooled
stable cell lines were treated with 6 Gy ionizing radiation. Protein was extracted 24 hours
after irradiation. Western blot demonstrated WT1 expression in U87MG after stable
transfection (top panel). Western blot demonstrated p53 expression in U87 stable
transfectants after treatment with 6 Gy ionizing radiation (bottom panel). B. U87MG cells
were treated with 6 Gy ionizing radiation. Viability assay based on cellular content of
ATP demonstrated a decrease in viability of the U87MG stable transfectants at 1 , 3, 5, and

7 days relative to non-irradiated cells. All treatments were performed in quintuplicate. C.
ATP viability assay demonstrated a decrease in viability of the U87MG stable transfectants
at 7 days after irradiation (n = 3).

days post-irradiation

VC

+I+

WT1 isoform

WT1 siRNA transfection increased sensitivity to radiotherapy. We then
determined if anti-WT1 strategies would sensitize glioblastoma cells to radiotherapy
independently of p53-mediated cell death pathways. We used T98G and LN-18 glioma
cells, both of which harbor p53 mutations and express endogenous WT1[30,92]. To
characterize the response of these cells to radiotherapy, cells were treated with increasing
doses of radiation and, 5 days after treatment, viability was assessed. Increasing doses of
radiation caused a progressive decrease in percent viability relative to untreated controls in
both cell lines (Figure 3-4A). Further analysis determined the EDso dose (dose expected to
cause a 50% decrease) of ionizing radiation to be 7 Gy for T98G and 5 Gy for LN-18.
Cells were then treated with the respective EDs0 dose of radiation, and percent viability
was measured at 1,3,5,7, and 9 days. In both cell lines, viability decreased to a minimum
at 5 days after which they began to recover (Figure 3-4B). Subsequent cytotoxicity
experiments were performed at the EDs0 doses and responses measured at 5 days postirradiation. To confirm that ionizing radiation caused a decrease in the capacity for
clonogenic survival, LN-18 cells were subjected to increasing doses of irradiation. Eight
days after treatment, Giemsa staining demonstrated a decrease in fractional survival
relative to nonirradiated cells with an EDsoof 2 Gy (Figure 3-4C).
We then tested the efficacy of siRNA targeting WT1 in these cell lines. T98G and
LN-18 cells were transfected with siRNA and relative WT1 protein levels were measured
96 hours later. Western blotting demonstrated that WTl protein expression was inhibited
at 96 hours post-transfection in T98G (Figure 3-4D, inset) and LN-18 (Figure 3-4E, inset).
Densitometric analysis of levels of WT1 normalized to cyclophilin A showed that WT1
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protein expression was decreased by almost 100% at 96 hours in T98G cells and LN-18
cells.
To determine if WTI targeting could improve the response to radiotherapy, we
transfected the cells with WTl siRNA and 48 hours later subjected them to EDs0 doses of
ionizing radiation. Viability assays performed 5 days after irradiation showed a
significantly larger decrease in viable cells pre-treated with WT1 siRNA than either
untransfected or vehicle treated T98G (Figure 3-4D) and LN-18 cells (Figure 3-4E). T98G
cells transfected with WT1 siRNA followed by irradiation had a 42.5% viability while
those untransfected or treated with vehicle alone had 68.8% and 55.8%, respectively (p <
0.0001). LN-18 cells had a 43.2% viability after combination treatment, compared to
87.2% and 73.7% for untransfected and vehicle alone, respectively (p < 0.0001). In
addition, WTI siRNA caused a smaller, but still significant, decrease in fractional survival
after irradiation in LN-18 cells as measured by the clonogenic survival assay (p < 0.0001,
Figure 3-4F). The fractional survival of cells transfected with WTl siRNA after irradiation
was 0.38, while untransfected cells and those treated with vehicle alone had a fractional
survival of 0.50 and 0.47, respectively.
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Figure 3-4. Effect of ionizing radiation combined with WT1 siRNA treatment. A.
T98G and LN-18 cells were treated with increasing doses of ionizing radiation and at 5
days after treatment percent viability relative to non-irradiated cells was then measured by
an ATP based cell viability assay. B. T98G and LN-18 cells were treated with their
respective EDsoof ionizing radiation and percent viability was measured at 1,3, 5,7, and 9
days post-irradiation. C. LN-18 cells plated at very low density were subjected to
increasing doses of ionizing radiation. After 8 days colonies were stained with Giemsa and
counted to determine the fractional survival relative to untreated cells. T98G (D, inset) and
LN-18 (E,inset) cells were treated with siRNA and protein was extracted at 24 and 96
hours after transfection. Western blotting demonstrated knock-down of WT1 protein.
Blots were re-probed with anti-cyclophilin A to control for equal protein loading. AntiWTl siRNA decreased viability of T98G (D) and LN-18 (E) human glioblastoma cells
after treatment with ionizing radiation. Cells either remained un-transfected, or were
treated with Oligofectamine vehicle or siRNA. After 48 hours, cells were treated with
their respective EDso of ionizing radiation. Luminescent cell viability assay was
performed 5 days after irradiation. The data is presented as percent viability of the
irradiated cells relative to non-irradiated controls which underwent the same transfection
procedure. Error bars represent the standard deviation. Graphs are representative of three
experiments with similar results.

* p < 0.01 by Tukey's HSD.

F. LN-18 cells were

irradiated 48 hours after treatment with siRNA. Giemsa staining and colony counting were
performed 8 days after irradiation (n = 3). Error bars represent the s.e.m.

* p < 0.01 by

Tukey-Kramer HSD; UT, untransfected; Of, oligofectamine alone; Si, siRNA
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Discussion
Based on reports in the literature, we hypothesized that WT1 would be involved in
glioma cell response to radiotherapy by inhibiting p53-mediated apoptosis[l36]. To
examine this possible interaction, we overexpressed WTl(+/+) and (-I+) isoforms in LN229 glioblastoma cells and found that WT1 expression did not inhibit apoptosis induced by
transient p53 transfection. Likewise, we found that WTl overexpression in U87MG cells
did not protect against p53-mediated cell death in response to irradiation. We then used
WT1 siRNA to silence WT1 expression in T98G and LN-18 glioblastoma cells, both of
which harbor p53 mutations. We found that WTl silencing increased radiosensitivity as
demonstrated by a decrease in viability and clonogenicity after treatment with ionizing
radiation.
The effect of WTl on apoptosis is highly variable. Both pro- and anti-apoptotic
effects have been described, depending on the cell type and tissue studied[48, 1441. Low
levels of WT1 inhibit apoptosis by interaction with p53[136]. In the same study, the
functional interaction was primarily studied using the WTl(-KTS) isoforms, however a
more modest anti-apoptotic response was observed with WTl(+KTS) isoforms as well.
We chose to study the WTl(+KTS) isoforms in this work because we have previously
shown that gliomas express WTl(+KTS) isoforms exclusively[30]. High levels of WT1
induce apoptosis independently of p53 in osteosarcoma cell lines. This apoptosis is
associated with down-regulation of the epidermal growth factor receptor (EGFR) and
induction of p21[48,49]. However, these studies only show an effect of WT1(-KTS)
isoforms. Nevertheless, apoptosis induced by high levels of WT1 in the stably transfected

104
cell lines used in this study may have masked the WT1-p53 interaction. Studies examining
the effect of lower levels of WT1 on p53 mediated cell death in human glioblastoma cells
are ongoing. Here we showed that the cell death associated with wild-type p53 in LN-229
glioblastoma cells correlated with an approximately 10% increase in apoptotic cells. It is
therefore possible that some of the decrease in viability was due to p53-dependent nonapoptotic mechanisms, such as cell cycle arrest, autophagy, senescence, or
differentiation[33, 2481. No studies to date have examined the ability of WT1 to inhibit
these p53 responses,
WT1 also inhibits apoptosis by p53-independent mechanisms. WT1 directly
upregulates Bcl-2 in cell lines of different p53 status[l44]. This upregulation of the antiapoptotic protein protects cells from apoptosis induced by DNA damaging chemotherapy
agents. Conversely, WTl siRNA targeting WTl(+exon5) isoforms induces apoptosis in
leukemia cell lines which is associated with up-regulation of the pro-apoptotic Bcl-2
family member Bax[93]. In the same study, Ito et al, demonstrate that overexpression of
WT1 protects leukemia cells from apoptosis induced by chemotherapeutic agents which is
associated with downregulation of Bak. In addition, WT1 modulates the expression of
EGFR[127] and platelet-derived growth factor (PDGF)[255]. These growth factors and
receptors participate in glioma cell resistance to radiotherapy[28, 841. The effect of WT1
silencing on radiosensitivity observed in this study may be due to p53-independent effects
of WT1 on the transcription of these genes.
In addition to p53, other protein-protein interactions modulate the activity of
WT1[210]. WT1 physically interacts with the other members of the p53 family of
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proteins, p73 and p63[209]. In this study, Scharnhorst et al. show that WT1 inhibits p73mediated transactivation, while p73 reciprocally inhibits DNA binding by WT1. Both p73
and p63 induce apoptosis and are involved in the cellular response to ionizing
radiation[268, 2071. WTl(+exonS) isoforms also physically bind to the prostate apoptosis
response factor, par4, and inhibit par4-mediated cell death in response to radiation and
chemotherapy. Par4 also modulates the function of WT1 as a transcription factor[200].
Therefore, the presence or absence of factors that interact with and modify the function of
WT1 in the different cell lines used in this study could be responsible for the differential
results obtained from the overexpression and silencing series of experiments.
In contrast to previous studies in other non-glioma cell lines, here we show that in
human glioblastoma cell lines, WTl does not protect against p53-mediated apoptosis
induced by either p53 overexpression or ionizing radiation. This study documents for the
first time that WTl in gliomas is unlikely to be functionally related to these cellular
responses in gliomas, and underscores the reported cell and tissue type dependence of WT1
function. Nevertheless, we show that WT1 silencing by siRNA can improve the
radiosensitivity of glioblastoma cells independently of p53-mediated cell death pathways.
This suggests that anti-WT1 therapies may have the potential to improve the response of
human brain tumors to radiotherapy. Further study of the molecular mechanisms of WTl
function in gliomas promises to identify strategies to improve glioblastoma radiosensitivity
in an effort to improve prognosis of this difficult disease.
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Abstract
Wilms' tumor 1 (WT1) is overexpressed in many human cancers, including
glioblastoma. We have previously shown that transient WT1 silencing increases
radiosensitivity in glioma cells. Studies of non-glioma cell lines demonstrate that WT1
promotes cell proliferation and survival. However this has not been rigorously studied in
glioblastoma. We tested the efficacy of two sequences of short hairpin RNA (shRNA)
directed against WTl in U251MG human glioblastoma cells and found that one sequence
was capable of stably silencing WT1 expression. Stable WT1 shRNA expression
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significantly decreased the proliferation of U25 1MG cells in vitro demonstrated by both
ATP-based viability assay and tritiated thymidine uptake. Furthermore, stable WT1
silencing caused significantly slower growth after inoculation of tumor cells
subcutaneously in the flanks of athymic nude mice and was associated with an increased
latency period. These studies provide proof of principle that downregulation of WT1
causes decreased tumorigenicity of a glioblastoma cell line in vitro and in vivo, and suggest
that WT1 may be a promising target for novel glioblastoma molecular therapies perhaps in
combination with standard treatment modalities.
Introduction
Glioblastoma multiforme (GBM) is a WHO grade IV glial tumor that carries a
universally poor prognosis with a median survival of one year after diagnosis[27].
Aggressive surgery, combined with radiotherapy and adjuvant chemotherapy, modestly
improves survival; however glioma cell resistance to standard treatments remains a major
obstacle. This is due, in part, to the high proliferative capacity and profound invasiveness
of glioma cells[20,22]. Decades of intense research have uncovered several molecular
mechanisms of glioma cell tumorigenicity[l34]. Despite these advances, a significant
clinical improvement has not been realized. Therefore, a more complete characterization
of the molecular mechanisms of tumorigenicity is necessary to uncover targets for novel
therapies. Previous studies by our laboratory and others have examined the expression of
the Wilms' tumor 1 (WT1) gene in human brain tumors, including gliomas of all grades,
and have found detectable expression in tumor cells but not in normal cells, suggesting an
important role for WTl in glioma biology[30, 178, 152,431. We have also shown that
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WT1 silencing increases radiosensitivity of glioblastoma cell linesa. Oji et al., demonstrate
that downregulation of WT1 using antisense oligodeoxynucleotides (ODN) decreases
viability of glioma cells 72 hours after transfection[l78]. However no studies to date have
extensively characterized the relationship between WT1 expression and tumorigenicity in
gliomas.
WTl was originally discovered as mutated in nephroblastoma, a common pediatric
kidney cancer also known as Wilms' tumor[23]. It was subsequently found that the wtl
gene, located at chromosome locus 1lp13, encoded a 52-55 kD polypeptide, the structure
and function of which designate it as a zinc finger transcription factor[l62]. Furthermore,
the message is alternatively spliced to generate four main isoforms, designated +I+, -I+, +/-

, -I-, depending on the inclusion or exclusion of exon 5 and nine nucleotides in exon 9
known as KTS, respectively[75]. WT1 (+KTS) isoforms, which gliomas express[30], may
be involved in RNA processing in addition to having both overlapping and unique
transcriptional properties relative to WT1(-KTS) isoforms. The functional significance of
exon 5 is less well understood, but may affect its interaction with other proteins[200].
Although originally classified as a tumor suppressor, WTl was later found to be
overexpressed in many types of cancer, including breast carcinoma and acute leukemia,
suggesting an oncogenic function for the gene[159,90]. WT1 overexpression causes
increased proliferation of cancer cells[239]. Inhibition of WT1 expression in human breast
cancer and leukemia cell lines using antisense modalities leads to differentiation, decreased
proliferation, and increased sensitivity to treatment[270, 31. Especially relevant to gliomas

a

Clark et al., "Down-regulation o f Wilms' tumor 1 expression in. .." manuscript in prep.
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which cause death by direct invasion and destruction of normal brain tissue, WT1
overexpression was recently shown to increase invasion of ovarian cancer cells[95]. Based
on the studies described above, we hypothesized that WT1 downregulation would decrease
the tumorigenicity of glioma cells. To test the hypothesis, we utilized U25 IMG human
glioblastoma cells, which express moderate levels of endogenous WTl. We generated
U25 1MG cells stably transduced with either empty vector or WT1 shRNA and examined
the effect on proliferation, invasion, and in vivo tumor growth.
Materials and Methods
Plasmid construction

Short interfering RNA (siRNA, Dharmacon) was tested for efficacy in cell culture
per the manufacturer's protocol (data not shown). Forward and reverse oligos were
generated using the provided sequence. Plasmid WT1 shRNA expression vectors were
constructed according to the manufacturers' protocol (pSUPER.retro.neo+gfp,
OligoEngine). Briefly, the pSUPER vector was linearized using HindIII and BclII
restriction enzymes. The annealed forward and reverse oligos were ligated into the
linearized vector with T4 DNA ligase (New England Biolabs, Inc.) to generate either
empty pSUPER vector or pSUPER.shWT1 expression vector. The vectors were then used
to transform DHSalpha bacteria (Invitrogen) selected with ampicillin. Plasmid purification
was performed using the QIAGEN plasmid mini kit (Qiagen). The presence of positive
clones was confirmed by EcoRI and HindIII digestion and sequencing. The packaging cell
line 293 T was then transfected with either empty pSUPER vector or pSUPER.shWT1
vector in addition to pCL-ampho packaging vector and pME-VSVg envelope vector using
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FuGENE 6 transfection reagent according to the manufacturers' protocol (Roche). After a
two day incubation at 37" C, media containing the retrovirus was harvested, filtered, and
stored in aliquots at -80" C.

Cell culture, viral transduction, sample preparation
U25 1MG, LN-18, and U87MG human malignant glioma cells were obtained from
American Type Culture Collection and were grown and passaged in Dulbecco's modified
Eagle's medium (DMEM) containing 10% fetal bovine serum, 1% glutamine, 1% nonessential amino acids, and 1% penicillin-streptomycin in a humidified atmosphere of 5%
COz. For transduction, cells were plated in six well plates at a density of 0.25 X lo6 cells
per well and allowed to attach overnight. Media was then replaced with 0.5 ml of infection
media (without fetal bovine serum) containing virus. Cells were incubated with gentle
agitation for 2 hours at which time 1.5 ml of media (with serum) was added to cells. After
viral transduction, cells were maintained in DMEM supplemented with 300 pglml of G418
(Geneticin, Invitrogen) which was exchanged every three days with fresh selection media.
Total RNA was isolated from cell lines using the Trizol extraction protocol (Invitrogen).
The concentration of RNA was determined by spectrophotometry. Protein was extracted
from cell lines using SDS buffer (50 mM Tris-C1, 1% SDS, 10% glycerol) supplemented
with protease inhibitors. The concentration of protein was determined by DC protein assay

(B ioRad).
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Western blot analysis
20 - 4.0 pg of protein was separated on a 4-1 2% Bis-Tris NuPAGE gel and
subjected to electrophoresis as per the manufacturer's protocol (Invitrogen). Protein was
transferred to a nitrocellulose membrane. The membrane was then blocked with 5% nonfat
milk solution for 1 hour at room temperature. Mouse anti-WT1 monoclonal antibody
(1 :200 dilution, DakoCytomation) was diluted in blocking buffer. The membranes were
incubated with primary antibodies overnight at 4°C. The membranes were washed six
times in Tris buffered saline containing 0.05% Tween-20 before and after a one hour
incubation at room temperature with horseradish peroxidase-conjugated anti-mouse
secondary antibody (1: 1000, Rockland, Inc.) for WT1. Blots were developed using the
ECL Detection System (Amersham Biosciences). Anti-Cyclophilin A monoclonal
antibody (1 :1000, Upstate Biotechnology) was used as a control for protein loadii~g.
Proliferation assays
Cells were plated in 5 replicate wells of 96 well tissue culture treated plates at a
density of 0.5 X lo3 cells per well. Cell viability was measured using the CellTiter-GLO
Luminescent Cell Viability Assay (Promega) at designated time points after plating.
Relative luminescence was detected on a Lumistar luminescence plate reader (BMG
)
was analyzed by plating in
Technologies). Tritiated thymidine O H - T ~ Ruptake
quintuplicate 0.5 X lo3 cells per well in 96 well, flat bottom tissue culture plates and
pulsing with 1 pCi of 3 ~ - at ~4 days
d (Arnersham
~
Biosciences). Cells were cultured for
an additional 18 hours and then stored at -80" C. Incorporation of H-TdR was used as a
measure of proliferation and was analyzed using a 96-well plate harvester and a beta-plate
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reader (Packard). Data are expressed as mean counts per minute (CPM) of quintuplicate
experimental cultures.
Invasion assay

A modified 96 well chemotaxis assay (Neuroprobe, Inc.) was used to monitor
tumor cell invasiveness. Assay chambers consisted of a fitted manifold with a porous
polycarbonate membrane (8 pM pores), pre-coated for 45 minutes at 37 "C with 25 pg/ml
growth factor reduced Matrigel (BD Biosciences; 50 pllwell). Cells were plated in 5
replicate wells at a density of 0.5 X lo4 cells per well. After 48 hours, media and cells
which had not invaded through the membrane were removed from the upper surface of the
manifold and 0.05 M EDTAJPBS solution added to each well, incubated at 37 "C for 15
minutes, prior to centrifugation of the plate at 300 X g. Cell growth medium was removed
from the lower chamber and fresh media added to each well. Collected cells in the lower
chamber were lysed for 10 minutes in Cell-titer Glo ATP viability assay reagents,
following the manufacturer's protocol (Promega). Cell lysates were transferred to opaque,
white-walled 96 well plates and relative luminescence detected on a Lumistar
luminescence plate reader (BMG Technologies). Two replicate independent assays were
performed.
In vivo tumor growth in nude mice

For inoculation, cells were first washed with sterile PBS and .then harvested by
trypsin-EDTA treatment. The dispersed cells were resuspended in sterile PBS and adjusted
to 3 x lo7 cellsJm1. Then 200 pl(6 x lo6 cells) of the cell suspension was injected
subcutaneously (s.c.) in the middle of backs of male 4 -6 week old athymic BALBJc nu/nu
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mice (Harlan Sprague Dawley, Inc.). For each of the three cell lines, 5 mice were
inoculated. Tumor size after injection was measured starting four days after inoculation
every two days for six weeks by dial-caliper and tumor volumes were calculated as (length
x (width2)) 12. Mice were euthanized when the tumor had reached 800 mm3. After
euthanasia, tumors were dissected from the skin and underlying muscle, snap frozen, and
stored at -80" C. Tissue was homogenized and protein extracted by SDS buffer and
sonication. Two replicate independent experiments were performed for a total of 30 mice.

Histological analysis
Tumor tissues were fixed in formalin, embedded in paraffin, and 5 pm serial
sections were prepared. A representative section was stained with hematoxylin and eosin
for histopathology. All slides were read in a blind manner. Microscopy was performed at
the VCU - Dept. of Neurobiology & Anatomy Microscopy Facility, supported, in part,
with funding from NIH-NINDS Center core grant (5P30NS047463).

Statistical analysis
Differences between two groups were analyzed by Student's t test. Differences
between three groups were analyzed by ANOVA followed by Tukey- Kramer honestly
significant difference test (HSD) as a post-hoc analysis. Differences between in vivo
growth rates were analyzed by repeated measures ANOVA.
Results

WT1 shRNA decreased proliferation. U25 1MG cells expressed high levels of
WT1 (Figure 4-1).

Figure 4-1. U251MG glioblastoma cells expressed WT1 protein. 40 pg protein
extracted from U25 1MG, LN-18, and U87MG cells was separated by SDS-PAGE and
examined for WTl expression by western blot. PC3 prostate carcinoma cell extract was
used as a positive control for WTl expression. U25 1MG cells expressed high levels of
WTl protein. U87MG cells did not express WT1 protein as we have previously shown
and served as a negative control. Anti-cyclophilin A antibody demonstrated low protein
loading in LN-18 cells, however a faint WTl band is observed. CypA, cyclophilin A
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Although protein loading was unequal, LN-18 cells expressed detectable WTl protein
while U87MG cells did not. These results confirm our previous characterization of WT1
expression in these cell lines[30]. We tested two sequences of shRNA targeting WTl,
referred to as 2N and 4N, for efficacy of WTl silencing in both U25 1MG and LN-18.
After three weeks of maintenance in selection media, protein was extracted and analyzed
by western blot for WT1 expression. Viral transduction with 4N shRNA resulted in a
marked decrease in WTl protein expression in both cell lines relative to cells transduced
with empty vector, while 2N did not (Figure 4-2a). All subsequent experiments utilized
4N shRNA transduced cells (now referred to as U25 1.Sh and LNl8.Sh). Each treatment
group was maintained as a pooled population of cells to eliminate the possibility of clonal
differences in growth characteristics affecting the growth measurements. Viral
transduction with either empty vector or WTl shRNA did not cause a change in
morphology of the cells relative to their respective parental cell line (Figure 4-2b). In
U25 1MG cells transduced with either empty vector (U25 1.VC) or WT1 shRNA containing
vector, the majority of cells expressed green fluorescence protein (GFP) demonstrating
stable expression of the plasmid vector (Figure 4-2c). The effect of WTl silencing on in
vitro proliferation was examined by ATP-based viability assay at 0, 1, 3, 5, and 7 days.

U251 .Sh cells proliferated at a significantly slower rate than U25 1.VC cells ( p < 0.0003,
Figure 4-2d). Tritiated thymidine incorporation performed at 5 days confirmed the
decrease in proliferation (p = 0.0003, Figure 4-2e). WT1 knock-down was maintained
throughout these experiments (Figure 4-2e, inset). WT1 silencing in LN-18 cells caused a
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less dramatic, but still statistically significant decrease in proliferation over the course of 5
days (Figure 4-20.

Figure 4-2. WT1 silencing decreased in vitro proliferation. A. U25 1MG and LN-18
cells were virally transduced with one of two sequences of WTl shRNA. After several
weeks of selection pressure, protein was extracted from the pooled population and
analyzed for WTl silencing by Western blot. B. Phase contrast microscopy demonstrates
the morphology of the parental and virally transduced cells. C. Fluorescence microscopy
demonstrates that the majority of U25 1MG cells transduced with the expression vector
stably expressed GFP (top panel). Light microscopy images are provided for comparison
(bottom panel). Magnification is 40X. D. ATP-based cell viability assay performed on
U25 1MG cells at 0, 1, 3, 5, and 7 days after plating demonstrates the decrease in
proliferation of U25 1.Sh cells relative to cells transduced with empty vector (U25 1 .VC).

*p < 0.0003 E. 3 ~ - uptake
~ dassay
~ performed at 5 days confirms that U25 1.Sh cells are
proliferating more slowly. Inset depicts western blot analysis of WT1 expression
confirming that WTl silencing was maintained at the time of the experiment. *p = 0.0003

F . ATP-based cell viability assay demonstrates the proliferation of LN18.Sh cells at 0, 1,
3, and 5 days after plating relative to LN18.VC cells. *p < 0.05

il.

WT1 silencing decreased invasion. Glioblastoma cell invasion into normal brain
is a major contributor to the tumorigenicity of these cells. We therefore analyzed the affect
of WT1 silencing on glioblastoma cell invasion by in vitro Matrigel invasion assay. After
48 hours, 63% fewer viable cells were present in the lower chamber of the in vitro invasion
assay apparatus in U25 1 .Sh cells relative to U25 1.VC cells ( p = 0.01, Figure 4-3).

Figure 4-3. WT1 silencing decreased in vitro invasion. U25 1 parental, U25 1.VC, and
U25 I .Sh cells were plated in the top chamber of a modified chemotaxis manifold on a
Matrigel-coated porous membrane. Two days after plating, the amount of cells that had
invaded through the membrane was quantified by viability assay and demonstrated that
U25 1.Sh cells exhibited lower invasion through the membrane. *p = 0.01, RLU, relative
luciferase units
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WT1 silencing decreased growth of tumor xenografts in nude mice. The
ultimate test of tumorigenicity is in vivo tumor formation. To test this, U25 1.Sh cells were
used to inoculate five nude mice subcutaneously in the flank and compared to five mice
inoculated with U25 1 parental and five mive inoculated with U25 1.VC cells. U25 1
parental and U25 1.VC cells formed tumors with very little latency period. U25 1.Sh
tumors remained undetectable for a significantly longer period of time relative to either
parental U25 1 cells or U25 1.VC cells (9 vs. 4 days, p = 0.01). Eventually tumors formed
in 100% of animals inoculated with either of the three cell lines. At all days, mice bearing
U25 1.Sh tumors had visibly smaller tumors than either U25 1 parental or U25 1.VC bearing
animals (Figure 4-4a). At 22 days post-inoculation, when the first animal was euthanized
for a tumor > 800 mm3, U25 1.Sh tumors were significantly smaller than U25 1 parental or
U25 1.VC tumors (U25 1.Sh, 156.0 mm3; U25 1, 570.6 n1m3; U25 1.VC, 720.5 mm3,p =
0.0004). U25 1 parental and U251 .VC tumors were not significantly different (p > 0.05).
Analysis of the growth curves revealed a significant decrease in growth rate of U25 1.Sh
tumors relative to U25 1 parental and U25 1.VC tumors (Figure 4-4b top panel, p < 0.0001).
Despite differences in growth rate, 100% of tumors reached 800 mm3 by 34 days postinoculation and were euthanized. However, U25 1.S11 tumors reached 800 mm3 in 3 1.3
days while U25 1 parental and U25 1.VC tumors took 26.4 and 23.6 days, respectively (p =
0.0028). A second independent experiment was performed with similar results (Figure 44b, lower panel). Histologic analysis of a subset of tumors demonstrated that all tumors
examined were densely cellular. Although the sample size is too small to derive any
conclusions, the U25 1.Sh tumors appeared to contain less cells undergoing mitosis,
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consistent with a lower proliferation rate(Figure 4-4c). Since the U25 1.Sh tumors
eventually formed large tumors, western blotting was performed on the excised tumors and
probed for WT1 expression to determine if WT1 shRNA expression had been lost. While
WT1 silencing was maintained at the time of inoculation in cell lines growing in culture,
all U25 1.Sh tumors regained WT1 expression by the time they had reached 800 mm3
(Figure 4-4d).

Figure 4-4. WT1 silencing decreased in vivo growth rate. Five athymic nude mice each
were inoculated with 6 X 1o6 U25 1 parental, U25 1 .VC, and U25 1 .Sh cells subcutaneously
in the middle of the back. Tumor growth was measured every two days until tumor had
reached 800 mm3. A. Photograph taken of representative animals from each group at day
16 post-inoculation demonstrated the difference in tumor size of U25 1 .Sh tumors relative
to U25 1 parental and U25 1 .VC tumors. The scalpel handle is shown for scale. B. Growth
curve demonstrated the slower growth rate of U25 1.Sh tumors. The in vivo growth
experiment was repeated with similar results (lower panel). Error bars represent the
standard error. C. When tumors reached 800 mm3, tumors were excised and forrnalin
fixed for tissue sectioning and hematoxylin and eosin staining. Histopathology
demonstrated densely cellular tumors. Arrows indicate mitotic bodies. Magnification is
indicated at the left margin. D. After excision, tumor tissue was snap frozen and protein
extracted for western analysis. Representative western blot of excised tumor protein
lysates demonstrated that WT1 was expressed by all tumors. WTI expression in protein
extracts from cells growing in culture is demonstrated for comparison.
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Discussion
To examine the affect of WT1 expression on glioblastoma cell tumorigenicity, we
generated U25 1MG and LN-18 human glioblastoma cells stably expressing shRNA
targeting WTl. Viral transduction with WT1 shRNA was capable of stably silencing of
the WTl gene over the course of multiple passages. WTl silencing significantly decreased
the proliferation of U25 1MG and LN-18 cells in culture. Interestingly, we observed a
decrease in viable cells that had migrated through a Matrigel-coated membrane suggesting
that WTl silencing decreased the invasive potential of U25 1MG cells. Most importantly,
WT1 silencing was associated with increased tumor latency and decreased growth rate in
vivo after inoculation in athymic nude mice.
The role of WT1 in glioblastoma has not been extensively characterized. The
results of this study suggest that one function of WTl in glioblastoma is to maintain the
high proliferative rate characteristic of the tumor. One previous study describes a decrease
in viability 72 hours after treatment of U87MG, A172, and T98G glioblastoma cells with
WTl antisense ODN[178]. Although their results correlate well with the cell proliferation
results presented here, our laboratory has shown in this study and previously that U87MG
cells do not express endogenous WT1[30]. Strangely, the manuscript does not include a
depiction of U87MG protein expression or of the efficiency of WT1 knock-down in any of
the cell lines examined[l78]. Studies of other cancer cell types also support a role for
WTl in increasing proliferation. Inhibition of WTl expression by antisense ODN in K562
and MM6 leukemia cell lines causes decreased proliferation and viability. ZapataBenavides et a1[270] show that WT1 antisense ODN treatment of breast cancer cell lines
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causes decreased proliferation which is associated with decreased cyclin D l , however
direct transactivation is not demonstrated. Furthermore, in MCF-7 and MDA486 breast
cancer cells, WTl directly up-regulates the expression of the proto-oncogene c-myc, a
known stimulator of proliferation[76]. These in vitro functional studies are potentially
clinically relevant as high WTl expression in both leukemia and breast cancer correlates
with worse prognosis[90, 1591.
Our results suggest a role for WTl in glioblastoma cell invasion. However, due to
the strong anti-proliferative effect of WT1 silencing observed in U25 1MG cells, we cannot
discount the possibility that the difference in viable cells that had migrated through the
Matrigel-coated membrane is due to a difference in proliferation and not invasion.
Although the relationship between WT1 and glioblastoma cell invasion has not been
previously reported, recent evidence suggests a role for WTl in cancer cell migration and
invasion. Jomgeow et a1 demonstrates that WT1 increases the invasion of TYK ovarian
cancer cells[95]. WT1 overexpression causes an increase in cell invasion as measured by
in vitro invasion assay. This is associated with a change in morphology possibly due to
WTl -mediated changes in cytoskeletal components; a decrease in a-actinin and cofilin
expression and an increase in gelsolin expression. A separate study demonstrates that
WTl regulates the E-cadherin promoter, a cell adhesion molecule involved in cancer cell
invasion[85]. Studies to confirm the role of WTl in glioblastoma cell invasion and to
determine the underlying molecular mechanism are ongoing in the laboratory.
Several studies have examined the effect of WTl over-expression on in vivo tumor
growth in nude mice. The results, however, have been contradictory. WTl (-KTS) isoform
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expression in transformed baby rat kidney cells increases tumor growth rate, while
WTl(+KTS) isoforms suppress tumor growth[l50]. Transfection of all isoforms of WTl
in Wilms' tumor cells increases tumor latency and decreases growth rate. Stable
expression of WTl (-KTS) in prostate cancer cells decreases in vivo tumorigenicity which
is associated with increased apoptosis and decreased expression of the WTl target Bcl2[5 11. In contrast to in vitro data described above in breast cancer cells, transfection of
MDA-MB-23 1 breast cancer cells with WTl completely prevents tumor formation in nude
mice which is associated with decreases p-catenin expression and activity. Likewise
subcutaneous or intraperitoneal injection of Ml murine leukemia cells overexpressing
WTl (+KTS) results in decreased tumor formation in severe combined immunodeficient
mice[226]. To our knowledge, ours is the first study to examine the affect of WTl
silencing on in vivo tumor growth. The results of our study relative to others may be
indicative of the well described cell-type specific responses of WTl or may reflect
differences inherent in comparing the response of overexpression of an exogenously
applied gene versus down-regulation of an endogenously expressed gene.
Although stable expression of WTl shRNA caused increased tumor latency and
decreased tumor growth in vivo, within 34 days the U25 1 .Sh tumors reached 800mm3.
The outgrowth of a tumor cell subpopulation could explain the accelerated growth rate
after a latency period. In fact, at the time of harvest, all tumors had regained WTl
expression as demonstrated by western blot. Protein contamination by non-tumor cells in
the tissue sample was not likely responsible for this observation as histologic examination
demonstrated that anaplastic tumor cells comprised the vast majority of the specimen.
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This suggests that the in vivo environment provided a selective pressure for the outgrowth
of clones which had lost WTl shRNA expression allowing increased proliferation. This
finding clearly demonstrates the importance of WT1 in supporting glioblastoma cell
proliferation and provides further evidence in support of an oncogenic function of WTI in
glioblastoma. Future studies focused on modalities capable of maintaining full WTI
silencing potentially may be able to halt in vivo experimental glioblastoma growth.
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CHAPTER 5.

GENERAL DISCUSSION
In this series of studies we aimed to characterize the expression of WT1 in human
glioblastoma and determine its function therein. This manuscript presents several novel
findings pertaining to the role of WTl in glioma biology. We show for the first time that

80% of glioblastoma tissue specimens express WTl (+KTS) isoforms, the expression of
which correlates with wild-type p53. Interestingly, lower grade gliomas, including those
of oligodendroglial origin, also express WTl. Unexpectedly, we found that WTl does not
protect against p53-mediated apoptosis induced by either transient transfection with wildtype p53 or ionizing radiation. We also show that WTl silencing using transient siRNA
transfection increases radiosensitivity of glioma cell lines. This is a finding that transcends
the field of neuro-oncology as it has not, to our knowledge, been reported in any other type
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of cancer. We utilized retroviral transduction with shRNA to stably inhibit WTI
expression which caused a decrease in proliferation and invasion in vitro. Furthermore,
glioblastoma cells stably expressing WT1 shRNA demonstrated decreased in vivo growth
rate in nude mice. To date, no other studies have shown that WTl silencing causes
decreased in vivo growth of cancer cells. We, therefore, have conclusively demonstrated
for the first time that WTI plays a major role in the tumorigenicity and resistance to
treatment of glioblastoma.
While several other studies have conclusively shown that WT1 physically and
functionally interacts with p53[136, 137, 871, we were unable to show such an interaction.
It could be argued that utilization of a different model of p53 induction could have yielded
superior results. However, in our studies we used both artificial (transient transfection)
and endogenous (ionizing radiation) methods to induce a p53 response. In both cases, cells
underwent cell death in response to p53 activation. Both of these sets of experiments
failed to show a modulation of p53-mediated cell death by WTI expression. In addition,
we attempted to use an LN-Z308 glioblastoma derived cell line stably expressing wild-type
p53 under the control of a doxycycline-inducible promoter[243]. Induction of p53 with
doxycycline resulted in upregulation of p53 protein, with no resultant decrease in viability
or detectable cell cycle arrest, thus negating its utility in studying a WTlIp53 interaction
(Appendix C). A potential alternative method of p53 overexpression is adenoviral
transduction which effectively induces apoptosis in glioblastoma cells[68], however this
was not used in this study. Nevertheless, based on the variety of techniques and cell
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backgrounds tested in our studies, it is not probable that WT1 interacts functionally with
p53 in relation to cell viability in glioma cells.
We also showed that, while WT1 overexpression in WTl non-expressing p53 wildtype glioblastoma cells (U87MG) did not affect radiosensitivity, WT1 silencing in WTlexpressing glioblastoma cells increased radiosensitivity. We also generated glioblastoma
cells of different p53 status (LN-229, p53 mutant; LN-Z308, p53 null) stably expressing
WTl and also found no difference in radiosensitivity, suggesting that the lack of WT1
induced radioresistance is applicable in general to glioma cells (Appendix D). An
explanation is that, when dealing with an aggressive transformed cell that is maximally
resistant to therapies, it is unlikely that the addition of one factor, such as WTl expression,
will cause an increase in resistance. This is particularly true in a complex disease process
such as glioblastoma in which several overlapping pathways contribute to radioresistance.
In this situation, it is more feasible to decrease resistance by silencing a gene that is
partially responsible for the resistance as we showed in our studies. The question as to
how WTI mechanistically contributes to radioresistance remains unanswered. Our studies
suggest that it is not due to interaction with p53 and subsequent inhibition of p53-mediated
apoptosis.
Thus, although these studies clearly support an oncogenic role of WT1 in
glioblastoma, the mechanism by which it functions remains unknown. As mentioned
above, in breast cancer cells WT1 transactivates c-myc which is known to promote
proliferation[76]. Because c-myc is also overexpressed in glioblastoma, we examined the
effect of WT1 silencing on c-myc protein expression by western blot and detected no
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difference in U25 1.Sh cells relative to U25 1.VC (Appendix E). There exist several other
candidates for mediators of the WTl effect on proliferation. EGF family members and
EGFR are known WT1 targets[l27, 1241. They play a critical role in glioblastoma
biology, in part by stimulating proliferation. In glioblastoma tissue, amplification and
mutation are the most common causes of EGFR hyperactivity. However, in established
glioma cell lines, EGFR amplification and EGFRvIII mutation are generally lost. Only
one described cell line exhibits EGFR amplification[233]. Therefore, other mechanisms of
up-regulation and activation of EGFR may be relevant to glioma cell behavior in culture.
WT1 transactivation of EGFR could be a potential mechanism. Likewise, WT1 mediated
up-regulation of EGFR stimulating ligands, such as Amphiregulin, may be responsible.
Likewise, in certain settings WT1 activates PDGF, a known regulator of glioblastoma
proliferation[255]. Unlike EGFR, amplification and/or mutation of PDGFR and its ligands
are rare events. The mechanism of PDGF overexpression in glioblastoma is currently
unknown. Future examination of the relationship between WTl and PDGF in gliomas
may uncover an unrecognized mechanism of PDGF upregulation.
The decrease in viability observed in cells transduced with WT1 shRNA could also
be due to increased apoptosis due to WTl silencing. As previously described, WT1 upregulates the anti-apoptotic protein Bcl-2 and may also regulate apoptosis via the proapoptotic protein Bax[144, 931. Again, we performed western blot analyses of U25 1.VC
and U25 1.Sh cell lysates and did not detect any difference in these proteins (Appendix E).
Other potential mediators of apoptosis potentially modulated by WT1 are pro-apoptotic
Bak and the anti-apoptotic Bcl-2 family member Al/BFL1[93,225]. Most of these studies
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were performed in leukemia cells which undergo apoptosis much more readily than
glioblastoma cells and, therefore, may display distinct patterns of gene expression in
response to pro-apoptotic stimuli. We have not yet performed apoptosis analysis of these
cells to determine the effect of WT1 silencing.
We detected a significant decrease in glioblastoma cell invasion following WT1
silencing. Glioblastoma cell invasion and destruction of normal brain continues to be one
of the most difficult components in the clinical management of the disease. To date, no
studies have examined the role of WTl in glioma invasion and few have examined its role
in invasion in other types of cancer. The few studies in other cell types have yielded
mixed results. A recent study demonstrates that WT1 overexpression in TYK ovarian
cancer cells leads to increased motility and invasion[95]. This increase in invasion is
associated with changes in cytoskeletal proteins, but a direct mechanism of WTl f~~nction
is not described. In NIH-3T3 fibroblasts, WTl overexpression leads to up-regulation of Ecadherin[85]. This observation contrasts with our results and those of the previous study
as E-cadherin loss is associated with increased invasion, therefore WT1 mediated
transactivation of E-cadherin would be expected to decrease invasion. When interpreting
the applicability of these studies, it is important to consider the cell-type dependence of
WTl transcriptional activity. Because the MT2-MMP promoter contains several WTl
binding sites and is relevant to glioma invasion, we examined the expression of MT2MMP after WT1 silencing (Appendix E). We found no change in the levels of MT2-MMP
protein. Screening of other MMPs relevant to gliomas is currently underway in the
laboratory.
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The role of WTl in glioblastoma may be more far-reaching than examined in this
set of studies. As we detected WTl expression in astrocytomas of all grades, it is possible
that WTl is also functioning at earlier stages of gliomagenesis. In the study of the earliest
stages of gliomagenesis, an important question is the cell of origin of glioblastoma. The
determination of the cell of origin has been difficult, particularly since the discovery of
adult neural progenitor cells capable of proliferating and differentiating into the mature
cells of the brain and, therefore, hypothetically able to undergo malignant transformation to
form a glioblastoma[l94]. A theory which incorporates these ideas posits that
astrocytomas arise from mature astrocytes that dedifferentiate into highly proliferative
immature cells in response to genetic mutations. Recent evidence in mouse models
supports this theory. Uhrbom et a1 report increased frequency of glial fibrillary acidic
protein (GFAP) positive brain tumors with histologic features of glioblastoma in transgenic

6rnk4a-Arf
null mice in which mature astrocytes were specifically infected with a virus
containing Akt and Ras[242]. These data suggest that a combination of genetic changes
can induce dedifferentiation of astrocytes which are then capable of forming glioblastoma.
Given that WT1 is preferentially expressed by undifferentiated leukemia and breast cancer
specimens[l85,223], WTl overexpression decreases differentiation in leukemia cell
lines[91,229,3,44], and WTI inhibition causes differentiation in the breast cancer cell
lines[239], it seems probable that WTI functions in some cancer types to maintain the
undifferentiated phenotype. In fact, several WT1 target genes have been shown to induce
dedifferentiation in astrocytes and subsequent tumor formation. Viral transduction of the
proto-oncogene c-myc in combination with Akt and Ras dedifferentiates astrocytes in
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culture and increases glioblastoma formation when used to infect mature astrocytes in
vivo[122]. WT1 transactivates c-myc as described above, however we showed that WTl
silencing in U251MG cells did not effect levels of c-myc protein. This represents an
observation in one glioblastoma cell line and needs to be replicated in others before a
generalization can be made. In contrast to the previous examples which required
combinations of gene transduction for dedifferentiation, infection of mature astrocytes with
PDGF caused recapitulation of the undifferentiated phenotype in vitro and increased tumor
formation in vivo[35]. As discussed previously, PDGF is a WT1 target gene and, similarly
to WT1, is expressed at an early stage in gliomagenesis. One can envision a mechanism
by which WT1 is aberrantly overexpressed by unknown factors which leads to
transactivation of c-myc and PDGF causing dedifferentiation of mature astrocytes and
maintenance of the immature phenotype. The affect of WT1 on astrocyte differentiation
has not been studied, but it would be interesting to determine the outcome of WT1
transfection into mature astrocytes alone or in combination with other genes.
Future directions
Athymic nude mice have been used successfully for decades to model human
tumor growth when inoculated subcutaneously with tumor cells[189]. This model has
provided invaluable data regarding tumor cell proliferation and efficacy of novel treatment
modalities. There are, however, several major limitations to this type of animal model,
particularly when applied to brain tumors such as glioblastoma. First is the absence of the
unique environment of the brain. Second is the lack of invasion of tumor cells into the
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normal tissue. Third is the lack of immune response. Future studies should include
models which are compatible with the examination of these important components.
Numerous studies have used U25 1MG heterotopic subcutaneous xenografts to
model human glioblastoma growth in vivo[155, 1031. Although the U25 1MG glioblastoma
cell line was used to inoculate nude mice subcutaneously in the flank, this cell line
possesses tumorigenic capacity in nude mouse brains also[204]. Future studies should
focus on replicating the subcutaneous flank tumor growth data in mice inoculated
orthotopically with U25 1MG cells stably expressing WT1 shRNA in .the caudate nucleus.
In this model, the animal is followed until onset of neurological decline, at which time the
animal is euthanized and the intracranial tumor is examined. The data is reported as
survival after inoculation. After replication of the data using stable cell lines, more
therapeutically relevant methods of knock-down should be tested. Our data demonstrating
a decrease in tumor growth by stable expression of WT1 shRNA provides proof of
principle that down-regulation of WT1 decreases in vivo tumor growth. A more stringent
test of therapeutic potential is decreased growth rate or tumor regression after infusion of
WTl shRNA, which more closely mimics the clinical scenario. Our laboratory has
extensive experience in the study of therapeutic delivery modalities in the brain which
could be combined with our use of WTl shRNA[15, 1901. Recently, direct intratumoral
injection of shRNA plasmid expression vectors into established intracranial gliomas has
induced down-regulation of target genes and subsequently affected tumor regression[69].
Replication of these results using WT1 shRNA would be a major step toward a potential
clinical trial.
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Studies examining the behavior of glioma cell lines and the tumor from which they
were derived show that in vitro invasion assays correlate well with in vivo
invasiveness[29]. This suggests that in vitro assays are valid models for studying glioma
invasion. Nevertheless, it is critical to test anti-invasive therapies in vivo to better
extrapolate efficacies in animal models to the clinical setting. Unfortunately, orthotopic
xenografts of established glioblastoma cell lines grow as discrete masses that compress,
but do not invade the mouse brain. Recently developed nude mouse models generate
tumors which more closely recapitulate the invasive characteristics of human glioblastoma.
Researchers obtain tissue biopsies during glioblastoma resections, process the fresh
specimens, and immediately implant the suspension in the flanks of nude mice. After
several heterotopic passages in nude mice, the tumors are excised and cultured briefly.
Inoculation of the resulting cultures orthotopically in nude mice brains produces densely
cellular, mitotically active, and rapidly lethal tumors characteristic of malignant
astrocytomas[61]. The study also shows that the tumors retained several genetic
characteristics of the patient tumors, including EGFR amplification. The tumors also
readily invaded the host brain along white matter tracts in some cases leading to
leptomeningeal spread and in one case gliomatosis cerebri mimicking the human disease.
A follow-up study demonstrates the utility of the model. Using this model, EGFR
inhibition combined with radiation therapy caused increased survival[206]. After
characterization of the xenografts for WT1 expression, an experiment could be designed to
examine the efficacy of WTl silencing strategies in decreasing in vivo glioma invasion.
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The models described above utilize immunodeficient mice to study the behavior of
human glioblastoma cells in vivo, but preclude the examination of the dynamic immune
response in brain tumor biology. Recent studies suggest, however, that the immune system
plays an important role in gliomagenesis. Scliwartzbaum et a1 report an inverse correlation
between asthma and other allergic conditions and glioblastoma in a large case-control
study[213]. In addition, they screened patients for polymorphisms in 5 genes known to be
involved in both allergic conditions and glioma or brain biology. They found that
polymorphisms in the pro-inflammatory genes interleukin receptor-4a (IL-4A) and
interleukin- 13 (IL- 13) were inversely correlated with glioblastoma and positively
correlated with asthma, suggesting that modulation of pro-inflammatory responses confers
risk of glioma developnlent. Animal studies in immunologically intact rats suggest that
these molecules may increase the immune system response to experimental gliomas.
Therefore, study of gliomas must include analysis of immune function. In vitro and in vivo
models exist to study and modulate the immune response to glioblastoma. Since WT1 is
expressed by the majority of glioma specimens and not by normal cells, it is an attractive
target for immunotherapy. Several mouse and rat brain tumor cell lines exist that could be
utilized to study the immune response to WTl expressing tumors. These cell lines could
be characterized for WT1 expression. An animal could then be immunized with WT1
peptide plus adjuvant or WT1-pulsed antigen presenting cells after which the animal is
challenged either subcutaneously or intracranially with the WT1 expressing tumor cell to
determine if the tumor is rejected.
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In spite of a lack of supportive animal data in glioblastoma, a clinical trial is
underway to examine the safety and preliminary efficacy of WTl peptide vaccination for
the treatment of refractory WT1-positive glioblastoma. The group reports that in a sample
of 5 glioblastoma patients, 1 demonstrated a partial response and 4 maintained stable
disease during the 12 week treatment period with minimal toxicity[l61]. Despite a paucity
of studies in experimental glioma, several studies have examined the efficacy of
immunotherapy targeting WT1 in other malignancies. Cytotoxic T lymphocytes (CTL)
generated against WTl peptide specifically lyse WT1 positive leukemia cell lines and
patient samples but not those that do not express WT1[172]. This response is specific to
undifferentiated leukemia cells which express a higher level of WT1 than either more
differentiated leukemia cells or WT1 positive normal hematopoetic progenitor cells which
are spared[55]. Mice vaccinated wit11 either WT1 peptide or WTl encoding plasmide
DNA generated WTl specific CTL capable of killing WT1 expressing leukemia cells and
induced immunity against tumor challenge without evidence of autoimmunity[182,238].
A small scale clinical trial involving 2 breast cancer, 10 lung cancer, and 14 leukemia
patients consisted of vaccination with WTl peptide and evaluation for change in tumor
size and adverse effects[l81]. Of the 20 patients available for evaluation, 12 demonstrated
the following clinical responses; decrease in tumor size (breast cancer), decrease in tumor
markers (lung cancer), decrease in blast cells (leukemia), or decrease in WT1 expression
(leukemia). An additional 2 patients maintained stable disease. A recent report
demonstrates that, although WT1 -specific CTL are present in draining lymph nodes of a
small sample of patients with stage 1 or 2 breast cancer, they were not capable of killing
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breast cancer cells without adjuvant stimulation[64]. Taken together, these results indicate
that vaccination strategies to activate endogenous impaired WT1-specific immune cells can
induce clinically detectable responses in patients with leukemia and solid tumors,
including glioblastoma.
Conclusion
Here we have shown that the majority of gliomas express WT1 while remaining
undetectable in normal human astrocytes. Functional studies demonstrated that WT1 is
critical for glioblastoma cell proliferation, invasion, radioresistance, and in vivo tumor
formation and growth. Future studies will undoubtedly discern the molecular mechanisms
by which WT1 exerts these effects and most likely will uncover an expanded list of
functions in glioma biology. As molecular diagnostic modalities become more refined and
prevalent, WTl may possess clinical utility in glioblastoma diagnosis and treatment.
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APPENDIX A
Decrease in WT1 mRNA expression in T98G glioma cells after 24 hours of
hypoxia.

Rationale. HIF-1 a transactivates the WT1 promoter in osteosarcoma cells exposed to
hypoxia[250]. Since HIF-la may play a critical role in the response of glioma cells to
intra-tumoral hypoxia, we examined the response of the WTl gene to hypoxia[94].
Methods. Cells were plated at a density of 1 X lo6 cells in 100 mm2 sterile tissue culture
dishes and incubated overnight for attachment. Cultures were then placed in a humidified
portable isolation Chamber (Billups-Rothenberg), flushed with a gas mixture of 1% O2
plus 5% CO2 plus 94%N2. A rate of 15 liters per minute was used to purge the
chamber for 3 minutes which yielded a concentration of 3% 0 2 . The entire chamber was
incubated 37" C for 24 hours, after which RNA was extracted from the cells followed by
real-time PCR analysis to detect WTl mRNA expression as described previously.
Differences between (+)hypoxia and (-)hypoxia within each cell line was analyzed by
Student's t-test. *denotes p = 0.0 14
Results and discussion. T98G cells demonstrated a significant decrease in WT1 mRNA
expression after exposure to hypoxic conditions while LN-18 cells demonstrated no
change. This possibly indicates a cell-type specific difference in WT1 response to
hypoxia, the mechanism of which is currently not known.

T98

LN18
Cell line
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APPENDIX B
Decrease in WT1 mRNA expression after neuronal differentiation of human NTera-2
cells.

Rationale. WTl is down-regulated in PC12 cells induced to differentiate into neurons by
NGF which is functionally important because it may be directly responsible for the downregulation of EGFR during the differentiation procells[l27]. In an effort to generalize this
observation, we examined the expression of WTl during the neuronal differentiation of a
different model system; retinoic acid induced differentiation of NTera-2 (NT-2) cells.
Methods. NT2 cells were maintained in ATCC modified DMEM (ATCC cat #30-2002)
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. For
differentiation, 2 X 1o6 cells were seeded in a 75 mm2 flask and treated with 10 pM
retinoic acid (RA) dissolved in DMSO. Cells were incubated at 37" C 5% C 0 2 for four
weeks with RA-containing media replaced three times a week. After four weeks of RA
treatment, cells were replated at a dilution factor of 1:6 in fresh 75 mm2 flasks and then
incubated for 24 hours at 37" C. Cells were then mechanically dislodged and floating cells
were replated on Matrigel (BD Biosciences) diluted 1:60 in 100 mm2 plates. After a 24
hour incubation period, cells were again mechanically dislodged and collected. 7.5 X 1o6
cells were replated on Matrigel coated plates and incubated in media containing the mitotic
inhibitors cytosine arabinoside (1 pM), 5-fluoro-2'-deoxyuridine (10 pM), and uridine (10
pM). After 1 week in culture, media was changed to media containing mitotic inhibitor
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minus cytosine arabinoside, and maintained for 3 weeks. Cells were then trypsinized and
replated in six well plates coated with poly-L-lysine.
Results and discussion. WT1 mRNA was detectable in undifferentiated NT-2 cells but
fell to undetectable levels after retinoic acid induced neuronal differentiation. This
suggests that WTl may play a role in the differentiation process of NT-2 cells and PC12
cells, and may therefore by important for neuronal differentiation.
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APPENDIX C
Lack of p53 response in LN-Z308 cells stably expressing doxycycline inducible p53.

Rationale. To examine the effect of WTl on p53 mediated apoptosis and cell cycle arrest
we utilized a glioma cell line expressing wild-type p53 under the control of an inducible
promoter.
Methods. LN-Z308 cells expressing p53 under the control of a doxycycline inducible
promoter (LNZ.C2024, kindly provided by Dr. Erwin Van Meir) were plated at a density
of 2 X 10' cells per well of a six well plate and allowed to attach overnight. Cells were
then transfected as described previously with a mixture 0.5 pg plasmid expression vector
containing WTl(+/+) or (-I+) isoforms and 3 p1 Lipofectamine2000 (Invitrogen). For
viability analysis, the next day, cells were gently harvested by trypsin-EDTA treatment,
counted, and re-plated in 96 well tissue culture plates at a density of 1 X 1o3 cells per well.
After a 24 hour incubation, cells were treated with doxycycline to induce p53 expression.
Viability was analyzed at 1 and 3 days after induction by ATP-based viability assay (C).
At 24 hours after doxycycline treatment, RNA and protein were extracted. WTl mRNA
was expressed after transient transfection and was unaffected by doxycycline (A). WT1
and p53 were expressed after transient transfection and doxycycline treatment (B). For cell
cycle analysis, cells were treated with doxycycline in six well plates for 24 hours and
harvested. Cells were stained with propidium iodide and analyzed by flow cytometry (D).
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Surprisingly, p53 induction did not cause a change in either cell viability or cell cycle
distribution.

Results and discussion. Transient transfection of LNZ.C2024 cells with WT1 caused a
dose dependent increase in WT1 mRNA expression (Figure A). Addition of doxycycline
caused an increase in p53 expression which was not affected by WT1 transfection (Figure

B). However, p53 expression did not induce and change in viability or cell cycle
distribution (Figures C and D). We can conclude that LNZ.C2024 cells possess a
functional inactivation of p53. The mechanism is not known.

Lf d o x
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APPENDIX D
Appendix D. WT1 expression does not protect LN-229 or LN-Z308 cells from
ionizing radiation induced cell death.
Rationale. We examined the effect of WT1 overexpression on radiosensitivity in LN-229

and LN-Z308 cells.
Methods. For protein extraction, LN-229 and LN-Z308 glioblastoma cells stably

expressing WT1 (+I+) or (-I+) isoforms were plated at a density of 1 X 1o6 cells/100 mm2
plate and exposed to 6 Gy of ionizing radiation. 24 hours after irradiation, protein was
extracted and Western blotting performed as described above. For ATP-based viability
assay, 1 X 1o3 cells were plated per well of 96 well flat bottom tissue culture plates and
exposed to 6 Gy of ionizing radiation. Cells were lysed and viability extrapolated based on
ATP content at 1,3,5, and 7 days after irradiation. Results are reported as % viability of
irradiated cells relative to matched non-irradiated cells. All treatment groups were
performed in quintuplicate.
Results and discussion. A. Western blotting demonstrates that LN-229 cells transfected

with WT1 isoforms were stably expressing WT1 protein (top panel). WT1 expression did
not change after irradiation. ATP-based viability assay demonstrated a time-dependent
decrease in viability in LN-229 cells after irradiation (bottom panel). Stable WTl
expression did not protect LN-229 cells from cell death. B. Similar results were obtained
from LN-Z308 glioblastoma cells. C. ATP-based viability assays were repeated three
times at the 7 day time point and demonstrated the same lack of protective effect of WT1
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expression. We can conclude that in these two glioma cell lines, WT1 ovexpression does
not protect agains ionizing radiation-induced cell death,

1

3

5

Days post-irradiation

7

3

5

Days post-irradiation

LN-Z308
Cell line

APPENDIX E
Changes in previously described WT1 targets are not responsible for
decrease in proliferation and invasion after WT1 silencing
Rationale. WTl decreases the proliferation of U25 IMG glioma cells in vitro and in vivo
and may possibly affect in vitro invasion. In U25 1MG cells stably expressing WT1
shRNA we examined the expression of known WTl target genes that were potentially
involved in these processes.
Methods. U25 1, U25 1.VC, and U25 1.Sh cells were plated at a density of 1 X 106 cells
per 100 mm2 plate and allowed to attach overnight. The following day, protein was
extracted by SDS lysis buffer as described previously. 20 pg of protein was separated by
SDS-PAGE and transferred to nitrocellulose membrane. After blocking for 1 hour in 5%
milk, membranes were incubated overnight at 4" C with anti-WT1 (1 :200, Dako
Cytomation), anti-c-myc (1 :100 dilution, Santa Cruz Biotechnology), anti-Bcl-2 (1 :100,
Calbiochem), anti-Bax (1 :300, Dako Cytomation), or anti-MT2-MMP (1 :2000, Chemicon).
Membranes were washed six times with TBS-T and incubated with their corresponding
secondary antibody for 1 hour at room temperature; anti-rabbit (1 :2000) for Bax and cmyc, anti-rabbit (1 5000) for MT2-MMP, anti-mouse (1 :2000) for Bcl-2, and anti-mouse
(1 :1000) for WT1. Membranes were again washed and protein was detected using the
ECL detection system.
Results and discussion. There were no significant differences in WTl target gene
expression between U25 1.VC and U25 1.Sh protein lysates, suggesting that the decreases
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in proliferation and invasion are due to WTl mediated changes in other targets that remain
to be discerned.
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